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ABSTRACT 
 Mycobacterium tuberculosis (M. tuberculosis) contains a wide array of genes 
responsible for the synthesis and secretion of a variety of bioactive lipids. The genes 
represent attractive drug-targets due to their involvement in essential cell cycles, the 
implication in pathogenesis, and the interference with therapeutics. In this thesis, I report 
our efforts to understand the biological functions of, and to develop inhibitors against, 
multiple genes related to M. tuberculosis lipid metabolism. Firstly, dioctylamine, a 
substrate mimic of the mycolic acid cyclopropane synthases, is shown to inhibit CmaA2 
in vitro. Its inhibition action is explained by the structural characterization. Together 
with our collaborators, we have found dioctylamine able to intervene multiple mycolic 
acid cyclopropane synthases in vivo, and hence established the first model study for the 
single-drug-multiple-target strategy to inhibit the mycolic acid biosynthesis of M. 
tuberculosis. In addition, dioctylamine can serve as the platform for the design of more 
potent and selective drugs in the future. Secondly, the action mechanism of isoniazid and 
ethionamide, both of which are pro-drugs targeting the mycolic acid biosynthesis, is 
explored via biochemical, X-ray crystallographic or modeling studies. We have 
determined that the intracellular target of isoniazid is the enoyl reductase InhA; and we 
have discovered the correlation between mycothiol and ethionamide susceptibility. 
Thirdly, I have investigated the function and mechanism of FadD10, an enzyme 
involved in the synthesis of a virulence-related lipopeptide. The results reveal that 
FadD10 was mis-annotated as a fatty acyl-CoA ligase, but it indeed transfers fatty acids 
to an acyl carrier protein (Rv0100). Further crystallographic characterization provides 
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the molecular basis for the mechanism of FadD10, leading to the discovery of a new 
type of adenylate-forming enzyme. 
	   	  
  iv 
TABLE OF CONTENTS 
 
 
  Page 
ABSTRACT ........................................................................................................................ ii 
TABLE OF CONTENTS ................................................................................................... iv 
LIST OF FIGURES ........................................................................................................... vii 
LIST OF TABLES ............................................................................................................. ix 
CHAPTER  
I  INTRODUCTION AND LITERATURE REVIEW .............................................. 1 
Mycobacterium Tuberculosis Lipid Metabolism Harbor Virulence Factors 
And Drug Targets ............................................................................................... 1 
Mycolic Acids ..................................................................................................... 3 
The biosynthesis and functions of M. tuberculosis mycolic acids .............. 3 
Direct inhibitors and pro-drugs targeting mycobacterial 
mycolate biosynthesis ................................................................................. 7 
Prospects of the M. tuberculosis CMASs as drug targets ......................... 11 
Complex Surface Lipids ................................................................................... 13 
FASs, PKSs, and NRPSs are responsible for the synthesis of complex 
lipids .......................................................................................................... 13 
Complex lipids in M. tuberculosis ............................................................ 16 
Other virulence factors related to complex lipids biosynthesis in M. 
tuberculosis ............................................................................................... 20 
II MYCOLIC ACID CYCLOPROPANATION IS ESSENTIAL 
FOR VIABILITY, DRUG RESISTANCE AND CELL WALL 
INTEGRITY OF MYCOBACTERIUM TUBERCULOSIS ............................... 25 
Summary ........................................................................................................... 25 
Introduction ....................................................................................................... 26 
Results ............................................................................................................... 29 
Deletion of cmaA2 from BCG pasteur is only possible after 
complementation with a functional mmaA3 ............................................ 29 
Dioctylamine inhibits multiple pathways of mycolic acid 
modification ............................................................................................. 33 
Mycolic acid methyltransferases are direct targets of dioctylamine ........ 36 
Dioctylamine inhibits the methyltransferase activity of CmaA2 in  
vitro .......................................................................................................... 38 
The structure of CmaA2 with bound dioctylamine reveals the 
  v 
molecular basis for activity ...................................................................... 40 
Dioctylamine is a growth inhibitor of BCG and M. tuberculosis ............ 43 
Mycolic acid modification is required for acid fastness and intrinsic 
resistance to antibiotics ............................................................................ 46 
Discussion ......................................................................................................... 48 
Experimental Procedures .................................................................................. 51 
Bacterial strains and growth conditions ................................................... 51 
Construction of mutant strains ................................................................. 51 
Mycolic acid preparation and analysis ..................................................... 52 
Radiolabeled ciprofloxacin permeability ................................................. 52 
Production of M. tuberculosis CmaA2 .................................................... 53 
Crystallization and data collection ........................................................... 53 
Structure determination and model refinement ....................................... 54 
Enzymatic assay for CmaA2 .................................................................... 54 
Additional Unpublished Results ....................................................................... 55 
Dioctylamine binds to CmaA2 in vitro .................................................... 55 
Fragment-based screening of ligands for CmaA2 ................................... 57 
Additional Unpublished Experimental Procedures ........................................... 62 
Determination of dissociation constant by fluorescence titration ............ 62 
Differential scanning fluorimetry (DSF) ................................................. 63 
Saturation transfer difference (STD)-NMR ............................................. 63 
III  CRYSTALLOGRAPHIC AND MODELING STUDIES AID THE 
UNDERSTANDING OF PRODRUG MECHANISM ......................................... 64 
Introduction ....................................................................................................... 64 
Results and Discussion ..................................................................................... 68 
INH-NADP adduct formation was not observed in an E. coli-based 
activation system coexpressing katG and dhfR. ....................................... 68 
INH-NAD adduct was detected in the E. coli based activation 
system co-expressing katG and inhA. ...................................................... 69 
Spontaneous mutants of M. tuberculosis, co-resistant to INH and ETH, 
map to mshA ............................................................................................. 72 
Comparison of the MshA structures of M. tuberculosis and 
Corynebacterium glutamicum establishes a rationale for the 
inactivation of MshA in the mutants ........................................................ 74 
Mycothiol promotes ETH activation by the ethA-encoded mono-
oxygenase ................................................................................................. 77 
Experimental Procedure .................................................................................... 79 
Cloning, expression, and purification ...................................................... 79 
Enzymatic assays ..................................................................................... 80 
Mass spectroscopy analysis ..................................................................... 80 
Crystallization of InhA in complex with INH-NAD 
adduct and data collection ........................................................................ 81 
Structure determination and model refinement ....................................... 81 
  vi 
Isolation of INH- and ETH-resistant spontaneous mutants ..................... 82 
MIC determination ................................................................................... 82 
EthA enzymatic activity assay ................................................................. 82 
IV STRUCTURES OF MYCOBACTERIUM TUBERCULOSIS FADD10 
PROTEIN REVEAL A NEW TYPE OF ADENYLATE-FORMING 
ENZYME .............................................................................................................. 84 
Summary ........................................................................................................... 84 
Introduction ....................................................................................................... 85 
Results and Discussion ..................................................................................... 90 
Crystal structures of M. tuberculosis FadD10 subunit ............................ 90 
A novel ligand-bound conformation of M. tuberculosis FadD10 ............ 95 
The conformation of M. tuberculosis FadD10 prevents Coenzyme A 
binding ..................................................................................................... 98 
Modeling studies of the interactions between M. tuberculosis FadD10 
and Rv0100 ............................................................................................ 101 
Substrate binding site of M. tuberculosis FadD10 ................................. 103 
Conclusion ...................................................................................................... 108 
Experimental Procedure .................................................................................. 109 
Cloning, protein expression, and purification ........................................ 109 
Crystallization ........................................................................................ 110 
Data collection and processing .............................................................. 111 
Structure determination and model refinement ..................................... 113 
Enzymatic assays to detect acylation of Rv0100 ................................... 114 
HPLC-MS analysis of dodecanoyl-amino acids .................................... 114 
Additional Unpublished Results ..................................................................... 115 
Kinetics of the adenylation activity of FadD10 ..................................... 115 
Gel filtration analysis of the interaction between FadD10 and 
Rv0100 ................................................................................................... 116 
Additional Unpublished Experimental Procedures ......................................... 117 
Enzymatic assays for adenylation activity ............................................. 117 
V CONCLUSION .................................................................................................... 119 
REFERENCES ................................................................................................................ 121  
APPENDIX AUTHOR CONTRIBUTIONS FOR THE REPRINTED ARTICLES ...... 141 
 
CHAPTER 
  vii 
LIST OF FIGURES 
FIGURE Page 
 
1-1. Schematic diagram of the architecture and chemical composition of the 
Mycobacterium tuberculosis cell envelope.  ............................................................ 4 
 
1-2. Schematic representation of the biosynthetic pathway of Mycobacterium 
tuberculosis mycolic acids. ...................................................................................... 6 
 
1-3. Structures of several direct inhibitors and pro-drugs that target the 
       Mycobacterium tuberculosis mycolate biosynthesis. ............................................... 8 
 
1-4. Schematic representation of the catalytic mechanisms of PKSs and NRPSs, with 
minimal configuration of domains shown with cognate key active site residues. ........... 14 
 
1-5. Acyl loading mechanisms discovered in the biosynthesis of complex lipids.  ...... 16 
 
1-6. Schematic diagram of the architecture and chemical composition of the 
Mycobacterium tuberculosis cell envelope. ........................................................... 17 
 
1-7. Structural and biochemical characterization of M. tuberculosis PKS11 led to the 
discovery of a new type of mycobacterial complex lipids. .................................... 22 
 
2-1. Chemical structures of the major mycolic acids of M. tuberculosis and BCG-R. . 27 
 
2-2. Genetic analysis of mycolic acid methyltransferase synthetic phenotypes. .......... 31 
 
2-3. Dioctylamine iInhibits multiple pathways of mycolic acid modification. ............. 34 
 
2-4. Mycolic acid methyltransferases are direct targets of dioctylamine. ..................... 37 
 
2-5. Dioctylamine inhibits CmaA2 in vitro. .................................................................. 39 
 
2-6. Structures of M. tuberculosis CmaA2 in complex with dioctylamine and 
DDDMAB/SAH. .................................................................................................... 43 
 
2-7. Dioctylamine inhibits growth of M. tuberculosis.  ................................................ 45 
 
2-8. Mycolic acid methyltransferases are required for drug resistance and acid 
       fastness of Mycobacteria. ....................................................................................... 47 
 
  viii 
FIGURE Page 
 
2-9. Dioctylamine binds to CmaA2 in vitro. ................................................................. 56 
2-10. Fragment-based screening for ligands that bind to CmaA2. ................................ 58 
3-1. The Fo – Fc map that is used to model the INH-NAD adduct into the active 
site of InhA. ........................................................................................................... 70 
  
3-2. Comparison of the MshA structures of M. tuberculosis and Corynebacterium 
glutamicum. ............................................................................................................ 76 
 
3-3. Mycothiol promotes ETH activation by the ethA-encoded mono-oxygenase. ...... 78 
 
4-1. Mutisequence-alignment of M. tuberculosis FadDs reveals a signature insertion 
for FAALs cluster.. ................................................................................................ 90 
 
4-2. The structures of apo- and complexed FadD10 with dodecanoyl-AMP. ............... 93 
 
4-3. The unique inter-domain interaction of FadD10 contributes to 
the conformational maintenance. ........................................................................... 96 
 
4-4. Modeling studies of the interactions between M. tuberculosis FadD10 and 
Rv0100. ................................................................................................................ 103 
 
4-5. Biochemical and structural analyses suggest the biological 
substrate of FadD10. ............................................................................................ 107 
 
4-6. Kinetics of the adenylation activity of FadD10. .................................................. 117 
 
4-7. Gel filtration analysis of the interaction between FadD10 and Rv0100 .............. 118 
 
  ix 
LIST OF TABLES 
TABLE Page 
 
2-1. Data collection and refinement statistics for CmaA2 
in complex with dioctylamine. ............................................................................. 42 
 
2-2. Lead fragments identified by DSF followd by STD-NMR .................................. 59 
 
3-1. Data collection and refinement statistics for InhA in complex with INH-NAD .. 71 
 
3-2. Point mutations in and deletion of mshA cause different levels of resistance to 
INH and ETH in M. tuberculosis. ........................................................................ 72 
 
3-3. The effect of mycothiol on EthA activity. ............................................................ 79 
 
4-1. Data collection and refinement statistics for FadD10 structures ........................ 113 
 
  1 
CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
Mycobacterium Tuberculosis Lipid Metabolism Harbor Virulence Factors And 
Drug Targets 
 Tuberculosis (TB), caused by the human pathogen Mycobacterium tuberculosis 
(M. tuberculosis), is a notoriously contagious disease infecting billions of people world-
wide. The World Health Organization (WHO) has estimated that ten percent of this 
population would develop active TB in their lifetimes. Previously, the mortality caused 
by the disease was usually accompanied by immune system deficiency of the patients, e. 
g. the young, the old, and especially the HIV virus carriers. But in recent years the cases 
of Multi-Drug Resistant (MDR) and Extensively-Drug Resistant (XDR) tuberculosis 
spurt world-wide, which has made TB an alarming threat to the global health. The 
typical treatment of TB is the combined use of several first-line drugs including 
ethambutol, isoniazid, pyrazinamide, and rifampicin. Yet almost 40 years after the first 
use of such therapy, the category is not expanded, and the application of most second-
line drugs is limited by availability, low efficacy, side-effect, or short half-life. The 
narrow choices of the chemotherapeutic reagents and lengthy treatment have led to the 
emergence of MDR and XDR-TB. Indeed, in 2010, the TB community had to exclude 
streptomycin, a veteran antibiotic that has ben used to fight against TB for decades, from 
the first-line treatment due to high rates of bacterial resistance to the drug(Roger Clark, 
2010). All these alarming facts have made the development of new anti-TB strategies 
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more urgent than ever. In this respect, extensive efforts have been made to understand 
the basis of M. tuberculosis infection, validate drug-targets, and design new drugs, 
facilitated by advanced informatic, genetic and proteomic tools. 
 M. tuberculosis, as one of the most persistent pathogen in the human society, has a 
very effective strategy to invade and sustain in human body. This is accompanied by a 
network of virulence factors that allow the bacteria to evade the human immune 
response, to adapt a living in host, and to withstand many antibiotics(Marina Forrellad et 
al., 2013). Along with the development of modern technologies, such as comparative 
genetics(Michelle Lopes Ribeiro-Guimarãesa and Maria Cristina Vidal Pessolani, 2007), 
transposon mutant library(Jyothi Rengarajan et al., 2005), high-throughput, 
proteomics(Sang Hyun Choa et al., 2006), numerous virulence factors of M. tuberculosis 
have been identified. The involvement of these factors span from essential metabolism, 
secretion systems, signal transduction, to interaction with host cells and defense against 
aggressive intracellular environment. Hence, many of them are considered promising 
targets for the development of new chemotherapies against TB. Multiple criteria, such as 
the non-homology to host(Baharak Khoshkholgh-Sima et al., 2011), the functional or 
structural acquisition(Solomon Nwaka and Alan Hudson, 2006), the feasibility to 
monitor inhibition in vivo(Tanjore Balganesh and B. J. Furr, 2007), have been taken into 
account to evaluate the duggability of these virulence factors. It is noteworthy that the 
enzymes involved in the mycobacterial lipid metabolism have always turned out as 
favorite picks in different approaches for prioritizing drug targets. 
 The deciphering of the M. tuberculosis genome reveals a large number of genes, 
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accounting for almost 20% of the open reading frames on the genome(Stewart Cole, 
1999), which are involved in the lipid metabolism. They are responsible for the 
biosynthesis of a wide variety of lipophilic products ranging from simple fatty acids to 
very-long-chain or branched species and to complexed lipids associated with multiple 
functional groups(S. T. Cole et al., 1998). A lot of them are unique to mycobacteria 
while absent in human being, and have been shown to play pivotal roles in the M. 
tuberculosis pathogenesis. Taken together with the potentially hydrophobic binding 
pockets implicated by their lipophilic substrates or products, the enzymes involved in the 
mycobacterial lipid metabolic pathways offer highly prioritized targets for the drug 
development against TB. Thus, understanding and eventually targeting these enzymes 
has become an essential and urgent subject in the field of M. tuberculosis studies. 
 
Mycolic Acids 
The biosynthesis and functions of M. tuberculosis mycolic acids 
 Cell wall is the key component in the M. tuberculosis cell envelope that enables 
the bacterium to thrive under the harsh environment inside human macrophage and 
intrinsically resist antimycobacterial agents(Mamadou Daffe and Philip Draper, 1998). 
This highly impermeable layer has a distinctive structure composed of three covalently 
linked macromolecules: peptidoglycan, arabinogalactan, and mycolic acids, as well as 
minor amount of embedded lipids. Mycolic acids are extremely long-chain (70-90 
carbons totally) α-alkyl β-hydroxyl fatty acids unique to mycobacteria. The α–branch of 
mycolic acids is a saturated chain of 22-26 carbons. The C40-C60 meromycolyl chain 
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bears two cis-double bonds with different modifications which define the three sub-types 
(α-, keto-, and methoxy-) (Figure 1-1) of mycolates found in M. tuberculosis. 
 
 
 
Figure 1-1. Schematic diagram(Hugues Ouellet et al., 2010) of the architecture and chemical 
composition of the Mycobacterium tuberculosis cell envelope. The chemical structures of three 
sub-types of mycolates (α-, keto-, and methoxy-), as well as the genes responsible for the 
concomitant modifications are shown in the right panel(Daniel Barkan et al., 2009). 
 
 
The biosynthetic pathways of mycolic acids have been largely, but not 
completely, understood over years of extensive studies(Evelyn Schroeder et al., 2002; 
Kuni Takayama et al., 2005) (Figure 1-2). Firstly, the type I fatty acid synthetase (FAS-
I), a modular enzyme elongating fatty acyl chain by repetitive catalytic cycles, produces 
saturated fatty acids up to C26. Secondly, the very long-chain meroacids are generated 
based on further elongation of the FAS-I products. This is performed by the type II fatty 
acid synthetase (FAS-II) system composed of discrete proteins that adopt the same 
catalytic mechanism as FAS-I but with different substrate preferences. How the two 
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double bonds are placed into the meroacids is unclear, however, it is likely to involve 
desaturase and isomerase activities(Evelyn Schroeder et al., 2002; Kuni Takayama et al., 
2005; S. T. Cole et al., 1998). Thirdly, different functional modifications are introduced 
to the distal and proximal double bonds on the meromycolyl chain by 8 paralogous S-
adenosyl-methionine (SAM) dependent methyltransferases, also called cyclopropane 
mycolic acid synthases (CMASs). The last step is the condensation between the fatty 
acyl and meromycolyl precursers, which is mediated by the gene products of fadD32-
pks13-accD4 cluster(Damien Portevin et al., 2005) and cmrA(David Lea-Smith et al., 
2007). The synthesized mycolyl molecules are then transported to the cell wall to 
esterify with arabinogalactan, glycerol or trehalose(John Belisle et al., 1997). 
In addition to a constructive role as one of the cell envelope components, M. 
tuberculosis mycolic acids have also been demonstrated an explicit involvement in 
pathogenesis and interference with clinical practice. First, they weigh in the 
sustainability and persistence of M. tuberculosis within the hostile environment of 
human macrophage. This is via forming biofilms(Anil Ojha et al., 2008), maintaining the 
viscosity of the cell wall(Clifton Barry III et al., 1998), controlling the permeation of 
nutrients(Clifton Barry III et al., 1998; Joaquim Trias et al., 1992), and et al.. Second, 
mycolic acids are heavily implicated in the mycobacterial virulence. The cell wall bound 
mycoloyl-arabinan induces secretion of tumor necrosis factor-α(IAkihiro Ishiwataa et 
al., 2006). The mycolated glycolipids non-covalently associated to the cell wall 
demonstrate strong adjuvant activities, including to inhibit the migration of blood 
leukocytes(Samuel Martin et al., 1950), to produce granulomatous inflammation(Yuriko 
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Ozeki et al., 1997), to induce strong antibody response(Bekierkunst et al., 1971), and et 
al.(Clifton Barry III et al., 1998; Michael Glickman and William Jacobs Jr., 2001). 
Third, the impermeable mycolate layer leads to several important features with respect to 
the diagnosis and treatment of TB, including acid-fast staining(Hajime Fukunaga et al., 
2002) and antibiotic resistance(Clifton Barry III et al., 1998). 
 
 
 
Figure 1-2. Schematic representation of the biosynthetic pathway of Mycobacterium 
tuberculosis mycolic acids. The acyl carrier protein (ACP) or ACP domain are colored blue. The 
enzymes or catalytic domains with β-keto acyl synthase (KS) activity, β-keto acyl reductase 
(KR) acitivity, dehydrase (DH) acitivity, and enoyl acyl reductase (ER) acitivity are  colored red, 
brown, green, and purple, respectively.  
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Direct inhibitors and pro-drugs targeting mycobacterial mycolate biosynthesis 
 Because of their crucial biological functions, the enzymes involved in the 
biosynthesis of mycolic acids represent promising drug targets for combating TB. 
Indeed, a number of effective inhibitors interfering mycolate synthesis have been 
discovered and some used in practice(Evelyn Schroeder et al., 2002), which has further 
convinced the efficacy and prospects to target this pathway. The mode of the inhibition 
by these drugs or candidates can be distinguished as either directly binding at the active 
site of a target enzyme or being structurally modified intracellular to become a direct 
binder to a target enzyme. 
 Multiple direct inhibitors (Figure 1-3), designed or adapted from known 
antiseptics, of the enzymes engaged in the mycolate biosynthesis have potent anti-
mycobacterial activity. For example, thiolactomycin, a natural product inhibitor of the 
keto-acyl-ACP synthase KasA, demonstrates excellent activity in mice(Satohide 
Miyakawa et al., 1982), and its analogues with improved stability and affordability are 
under development(James Douglas et al., 2002; Kanishk Kapilashrami et al., 2013). N-
Octanesulfonylacetamide, designed to mimic the transition state intermediate of keto-
acyl-ACP synthases, has promising antimicrobial activity in vitro(Nikki Parrish et al., 
2001). Several analogues of triclosan, a widely-used antiseptics that binds to enoyl-acyl-
ACP reductases, showed decent improvement in bactericidal effect after structure-
guided modifications(Joel Freundlich et al., 2009). 
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thiolactomycin N-octanesulfonylacetamide triclosan 
  
 
 
Figure 1-3. Structures of several direct inhibitors and pro-drugs that target the Mycobacterium 
tuberculosis mycolate biosynthesis. 
 
 
 Aside from the direct inhibitors, pro-drugs (Figure 1-3), which are converted to 
bioactive forms intracellular, have gained more pharmacological success in the treatment 
of TB. One outstanding example is isoniazid (INH), a first-line and the most prescribed 
anti-tubercular drug. The molecule INH itself is not toxic to the bacteria. However, once 
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activated by the M. tuberculosis catalase-peroxidase KatG, it is transformed into 
isonicotinoyl radical, followed by Minisci addition with NAD+ to form the adduct INH-
NAD(Martin Wilming and Kai Johnsson, 1999) which binds to the active site of the 
enoyl-acyl-ACP reductase InhA and strongly inhibits the enzyme (Ki = 0.75 nM)(Richa 
Rawat et al., 2003). (S)-INH-NAD, the bioactive form of INH, can be readied purified 
from the incubation of KatG with INH and NAD+ in vitro(Denise Rozwarski et al., 
1998). The structure of InhA co-crystallized with (S)-INH-NAD has identified the 
chemical structure of the active adduct, interpreted explicitly the molecular basis of the 
binding(Denise Rozwarski et al., 1998), and explained the resistance mechanism of a 
highly frequent clinical isolate M. tuberculosis S94A(Catherine Vilchèze et al., 2006). 
Though the chemically synthesized isomer (R)-INH-NAD showed ability to bind to 
several other enzymes in vitro(Argyrides Argyrou et al., 2006a; Argyrides Argyrou et 
al., 2006b), there is no evidence, up to now, for the presence of such isomer in cell. In 
other word, InhA is the only confirmed molecular target of the prominent anti-tubercular 
activity of INH(Feng Wang et al., 2010), which is elaborated in CHAPTER III. 
 Another clinically effective pro-drug via inhibiting mycolate biosynthesis is 
ethionamide (ETH). It was discovered by screening a series of INH analogues for anti-
tubercular activity(D. Gupta, 1977), and it indeed inhibits the same target (InhA) as INH. 
However, its activation is performed by a different enzyme that is the Baeyer-Villiger 
monooxygenase EthA(Marco Fraaije et al., 2004). Though having been used as a 
second-line chemotherapeutics since 1956 in the TB treatment, the active form of ETH 
was not identified until recently. Using a whole-cell based activation system, where M. 
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tuberculosis EthA and InhA were co-expressed by E. coli in presence of ETH, 
Sacchettini and associates(Feng Wang et al., 2007b) were able to isolate InhA bound to 
the bioactive adduct formed by ETH. Biochemical and structural characterizations have 
elucidated the compound to be ethyl isonicotinoyl-NAD (ETH-NAD). It is very similar 
to INH-NAD in both the structure and the binding mode in the InhA active site(Feng 
Wang et al., 2007b). EthA is clearly not as efficient as KatG to activate the cognate pro-
drug in vitro. The function of EthA can only be realized in vivo, while its in vitro activity 
(Kcat = 0.0063 s-1) is unusually low compared with the other homologous 
monooxygenases. This indicates that other cellular components are involved to complete 
the EthA function. We have found out that one of these factors is the reducing agent 
mycothiol by genetic, biochemical, and modeling studies(Catherine Vilchèze et al., 
2008), which are discussed in CHAPTER III. 
 Isoxyl (ISO) and thiacetazone (TAC), two pro-drugs for treating MDR-TB 
strains, are also implicated to interfere with the synthetic pathway of mycolic acids. Both 
drugs share a thioamide motif and a common activator EthA with ETH(Lynn Dover et 
al., 2007). Spontaneous ISO- and TAC-resistant mutations have been located at multiple 
genes responsible for the mycolate synthesis. They include CMASs (mmaA2, mmaA4) 
and hydroxyacyl-ACP dehydratases (had ABC)(Anna Grzegorzewicz et al., 2012). It is 
also shown that over-expression of CMASs (CmaA2, PcaA)(Anuradha Alahari et al., 
2007) or the desaturase (DesA3)(Benjawan Phetsuksiri et al., 2003) confers certain level 
of resistance to TAC or ISO. Though the bioactive metabolites and the precise 
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mechanism of TAC and ISO are still elusive, it is likely that their cellular targets are 
among the identified relevant enzymes. 
 
Prospects of the M. tuberculosis CMASs as drug targets 
 Certainly pro-drugs have exhibited chemotherapeutic values, but their 
disadvantages in drug development and clinical administration are obvious. First, the 
complication of a pro-drug’s mechanism makes the drug development more challenging. 
As discussed above, we still lack a lot of knowledge regarding their intracellular 
metabolism and functional mode. This has prevented the pursuit of a better inhibition 
and less side effects based on a known pro-drug’s structure. Second, the involvement of 
activating enzymes poses a higher chance for the development of drug-resistant mutants, 
which have been observed in numerous clinical isolates when patients are treated with 
pro-drugs(Andrea DeBarber et al., 2000; Angelo Scorpio et al., 1997; Stephen Gillespie, 
2002; Ying Zhang et al., 1992). Therefore, it is still our hope to pursue antimycrobials 
that can directly inhibit the enzymes in the mycolic acid synthetic pathway. 
 The improper usage of antibiotics and lengthy treatment have led to a steady 
increase of drug-resistant M. tuberculosis strains. The need for new anti-tubercular 
agents is more urgent than ever, especially to enable shorter-course therapy and to delay 
the occurrence of drug resistance. For this purpose, a very promising strategy is to use a 
single inhibitor against multiple targets(Richard Morphy and Zoran Rankovic, 2005). 
This prefers the targeted proteins to have similar binding affinity but non-redundant 
functions, exemplified by acyl-AMP analogues to inhibit several M. tuberculosis FadD 
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proteins which are involved in separate lipid synthetic pathways(Pooja Arora et al., 
2009). The CMASs also satisfy such criteria. 
 Eight SAM dependent CMASs are identified in M. tuberculosis, sharing a high 
sequence homology (~ 50% identity to each other). Cell-based analyses and in vitro 
experiment using radioactive precursors have determined their biochemical activities 
(Figure 1-1), except for CmaA1(Eugenie Dubnau et al., 1997; Laxman Meena et al., 
2013; Michael Glickman et al., 2000; Michael Glickman et al., 2001; Ying Yuan and 
Clifton Barry III, 1996; Ying Yuan et al., 1997). Separate knock-out strains of each 
CMAS have been generated and evaluated the physiological properties(Dee Dao et al., 
2008; Eugenie Dubnau et al., 2000; Michael Glickman et al., 2000; Pascale Peyron et al., 
2008; Vivek Rao et al., 2006; Vivek Rao et al., 2005). The studies reveal that each 
CMAS performs a distinct chemical modification on the meroacyl chain of M. 
tuberculosis mycolate and is implicated at a different stage of infection. In addition, five 
CMASs have been structurally characterized, which exhibit an apparent similarity in 
their active site composition(Chih-chin Huang et al., 2002; Fanny Boissier et al., 2006). 
This, coupled with the distinct biological functions of CMASs, suggests that CMASs are 
applicable as targets of a single drug. Indeed, we(Daniel Barkan et al., 2009) and Lionel 
Mourey et al.(Julien Vaubourgei et al., 2009) have independently showed dioctylamine 
(elaborated in CHAPTER II) and S-adenosyl-N-decyl-aminoethryl, respectively, able to 
inhibit multiple CMASs and consequently the mycobacterial growth. These studies 
together have unequivocally indicated CMASs as promising targets for the drug 
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development and have proven the feasibility to inhibit multiple CMASs simultaneously 
by a single compound. 
 
Complex Surface Lipids 
FASs, PKSs, and NRPSs are responsible for the synthesis of complex lipids 
 Complex lipids are based on simple fatty acids which are incorporated with a 
variety of functional groups including phosphate, glycosidic, peptidyl moieties, and et 
al.. They widely occur in nature, especially in plants and bacteria, as secondary 
metabolites, and demonstrate broad bioactivities such as antibiotics, surfactants, and 
virulence factors(Mohamed Marahiel et al., 1997). The major chemical scaffolds of the 
complex lipids are typically synthesized by three multifunctional enzymes that are fatty 
acyl synthase (FASs), polyketide synthases (PKSs) and non-ribosomal peptide synthases 
(NRPSs). They are similar in the architecture in terms of that all of them can occur as 
either modular multi-enzymes or enzyme clusters with discrete members. They are also 
mechanistically analogous in the way to catalyze repetitive reaction cycles (Figure 1-1, 
Figure 1-4). Together with these “megasynthases”(Timm Maier et al., 2008), other 
enzymes or functional domains are associated in the biosynthetic pathways of complex 
lipids. They are responsible for either the crosswalk between the multi-enzymes(Darren 
Hansen et al., 2007; Debasisa Mohanty et al., 2011) or the introduction of specific 
chemical modifications on the core structures(Deborah Miller et al., 2001; Thomas 
Keating et al., 2002). 
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A B 
 
Figure 1-4. Schematic representation of the catalytic mechanisms of PKSs (A) and NRPSs (B), 
with minimal configuration of domains shown with cognate key active site residues. Both ACPs 
(acyl carrier protein domains) of PKSs and PCPs (peptidyl carrier protein domains) of NRPSs 
are phosphopantetheinated so that to bear free thiol termini. The reactions catalyzed by both 
types of the enzymes undergo a process including: substrate loading, repetitive cycles of 
elongation, and product release. 
(A) For PKSs, in each reaction cycle, a malonoyl group is loaded by AT (acyltransferase 
domain) onto ACP; each elongation step involves decarboxylation of malonoyl followed by 
claisen condensation with the template acyl chain, mediated by KS (β-keto acyl synthase 
domain); the thioesterified product is eventually hydrolyzed and released by TE (thioesterase 
domain). 
(B) NRPSs require three domains to assemble peptides – adenylation (A), PCP, and 
condensation (C) domains. Each A domain selectively activates an amino acid substrate and 
loads in onto the cognate PCP. C domain catalyzes the nucleophilic attack from the downstream 
PCP-carried amino group to the upstream PCP-carried aminoacyl or peptidylacyl moieties, 
forming a new peptide bond. The final products are typically released by TE domain, similar to 
PKSs. 
 
Because of the chemotherapeutic values and physiological significance of 
complex lipids, tremendous efforts have been made to decipher their biosynthesis. Yet 
the territory seems borderless while novel mechanisms are discovered time after time. 
One example is the discovery of an acyl loading mechanism alternative to the 
predominant O-fatty acyl transferases (AT). The latter are found either as a catalytic 
domain of a multi-enzyme (mostly a FAS or PKS) or an individual enzyme. They use 
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selective fatty acyl-CoAs as substrates and are able to uptake the fatty acyl moieties by 
esterification with the conserved active site serine residue. The acyl chains are then 
transferred to ACPs for transport to other catalytic centers in a biosynthesis (Figure 1-5 
A). This acyl-CoA and acyltransferase dependent mode was the only recognized acyl 
loading mechanism for the biosynthesis of naturally occurred complex lipids, until 
recently an alternative scheme is discovered. In the new mechanism, an adenylate-
forming enzyme directly uses fatty acids to generate fatty acyl-AMPs as intermediates 
and transfer fatty acyl moieties to cognate ACPs for further process (Figure 1-5 B). The 
first biochemical presentation of such a mechanism was reported when the M. 
tuberculosis adenylate-forming enzymes FadD26, FadD30, FadD32 were shown to 
transfer the cognate fatty acid substrates to their cooperative PKSs, which are PpsA, 
PKS6, and PKS13, respectively(Omita Trivedi et al., 2004). The function of this 
subclass of adenylate-forming enzymes is further established with the demonstration of 
fatty acyl transfer by Bacillus subtilis ATP dependent acyl ligase AL onto the acyl 
carrier protein ACP1. Both proteins were isolated from the lipopeptide mycosubtilin 
synthetic pathway, and the acyl transfer occurred in absence of CoenzymeA or 
derivatives(Darren Hansen et al., 2007). This newly discovered activity of adenylate-
forming enzymes has been classified as fatty acyl-AMP ligases (FAALs) which are 
discussed more detailed later in this CHAPTER and CHAPTER IV. 
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Figure 1-5. Acyl loading mechanisms discovered in the biosynthesis of complex lipids. They 
can be catalyzed by, respectively, (A) a fatty acyl transferase (AT), and (B) a fatty acyl-
AMP ligase (FAAL). 
 
Complex lipids in M. tuberculosis 
 Analyses of the M. tuberculosis genome reveal the presence of a fas I gene, a fas 
II gene cluster, 2 nrps containing gene clusters, and 25 pks genes(S. T. Cole et al., 1998). 
Consistent with the variety of these genes related to lipid metabolism, an unusually large 
amount and diversity of complex lipids have been discovered in M. tuberculosis, which 
outweigh any other pathogenic bacteria. All of these complex lipids are found in the 
extract of M. tuberculosis cell envelope, and hence are likely to function in determining 
the physical properties of the cell envelope or mediating specific host-pathogen 
interactions. The lipid components anchoring at M. tuberculosis capsule are at minor 
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amount and their identities remain elusive. Other than that, multiple complex lipids 
associated to the plasma membrane and the cell wall are present at reasonable amount to 
be isolated and chemically characterized (Figure 1-6). 
 
 
Figure 1-6. Schematic diagram(Hugues Ouellet et al., 2010) of the architecture and chemical 
composition of the Mycobacterium tuberculosis cell envelope. The chemical structures of 
complex lipids, identified up to date, are shown in the right panel. 
  
Lipomannan (LM) and lipoarabinomannan (LAM) (Anna Grzegorzewicz et al.), 
two major mycobacterial glycolipids, are found to be non-covalently associated to the 
plasma membrane and extend their lipidic tails beyond the cell wall. Defects in 
LM/LAM synthesis result in an increased susceptibility of M. tuberculosis to β-lactam 
antibiotics which implies a higher permeability of the cell envelope(Takeshi Fukudaa et 
O
O
O
O
P
O
OH
O
O
O O
O
HO
HO
HOHO
HO
OH
O
OH
OH
HOHO
MannanArabinan
LAM
R
RO O
O OPDIM
O
O
O
O
O
O
HO
OH
-O4S
OH
O
O
O
OH
OH
O
SL
OHO
HO
OH
OH O
P
O
O
O-
MPM
OCH3O O
O OPGL
O
OHO
HO
HO
OCH3
O
O O
OH
OH
O
O
OH
OH
O
O
O
O
O
O
PAT Mycobactin
N O
NH
HN
O
O
O
N
O
HO
N OH
OH
 
 
 
  18 
al., 2013). The mannosyl cap of LAM is suggested to interact with the mannose receptor 
of human macrophage so that to induce cell entry at the early stage of infection(Jordi 
Torrelles and Larry Schlesinger, 2010). Complex lipids intercalated in the cell wall, as 
identified up to date, include phthiocerol dimycocerosates (PDIMs), sulfolipids (SLs), 
polyacyl trehaloses (PATs), mannosyl phosphomycoketides (MPMs), and phenolic 
glycolipids (PGLs). PDIMs are heavily implicated in the M. tuberculosis virulence 
especially at the early stage of infection(Cécile Rousseau et al., 2004). They can insert 
into the membrane of human macrophage and alter the lipid organization on the surface 
of the macrophage, which eventually facilitates the invasion of M. tuberculosis baccili 
into the host(Catherine Astarie-Dequeker mail et al., 2009). SLs are also abundant 
complex lipids, second to PDIMs, found in the M. tuberculosis cell wall. Apart from a 
role in maintaining the cell wall integrity, their precise function in virulence is not yet 
established as the compounds induce a wide-profile of transcriptional effects in human 
immature dendritic cells(Sarah Gilmore et al., 2012). PATs are located on the exterior 
surface of the cell wall. They have a wax nature to prevent the mycobacterial cells to 
clump with each other(Vinod Dubey et al., 2002). Yet there is no evidence for their 
contribution to virulence, the production of PATs responds to different stress 
environments in vivo(Kyle Rohde et al., 2007). MPMs are produced at a low amount in 
the slow-growing pathogenic mycobacteria. They display antigenicity via interacting 
with the human CD1 proteins that are produced by antigen expressing cells(Isamu 
Matsunaga and Masahiko Sugita, 2012). This has been delineated by the crystal structure 
of human CD1 protein in complex with the M. tuberculosis MPM(Louise Scharf et al., 
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2010). Mycobacterial PGLs are not observed in M. tuberculosis except for the 
hypervirulent Beijing strains. The lipids directly suppress the release of three different 
pro-inflammatory mediators of human macrophage, and consequently lead to the 
hyperlethality of certain M. tuberculosis strains(Michael Reed et al., 2004). M. 
tuberculosis Mycobactins are present either as associates to the cell wall or secreted 
molecules. The secreted mycobactins are responsible to extract extracellular iron, while 
the cell wall associated mycobactins store the iron for following acquisition into the 
cell(Minkui Luo et al., 2005).  
 The biosynthesis of complex lipids is as complicated as their structures, but 
genome sequencing, knock-out studies, and biochemical demonstrations have provided 
chances to decipher the synthetic pathways of the M. tuberculosis complex lipids. 
Except for LM and LAM, they all engage at least one PKS or NRPS multi-enzyme. 
Multiple PKSs annotated as PpsA-E are responsible to elongate and incorporate diol 
groups onto the phthiocerol chain of PDIMs; the mycocerosic chains are synthesized by 
another PKS annotated as Mas; and the phthiocerol dimycocerosyl transferase PapA5 
catalyzes the condensation between the mycocerosic and phthiocerol chains. The 
synthesis of PGLs shares the same core steps as PDIMs, except that a gene cluster of 
Rv2949-pks15-pks1 generates the phenolic precursor prior to the action of PpsA-E. 
PKS2 produces the long acyl moieties of SLs, and the acyltransferases PapA1, PapA2 
and Chp1link different acyl chains to the trehalose hydroxyl groups(Jessica Seeliger et 
al., 2012). PATs have similar chemical scaffolds, as well as synthetic scheme as SLs, 
just involving a different set of PKS (PKS3/4) and acyltransferase (PapA3). 
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Mycobacterial PKS12 is responsible to synthesize the long mycoketide chain of MPMs. 
Consistent with the discovery of MPMs, PKS12 is only found in the pathogenic 
mycobacteria. It catalyzes alternative and repetitive cycles of reactions to incorporate 
ethylene and isopropyl moieties into the growing chain(Tarun Chopra et al., 2008). 
However, no enzymes have been identified for the reduction, phosphorylation, or 
mannosylation step to generate the final products MPMs. The biosynthesis of 
mycobactins is carried out by a hybrid system of PKSs (annotated as MbtC/D) and 
NRPSs (MbtB/E/F) cooperated with the ligase MbtA, the salicylate synthases MbtI, the 
hydroxylase MbtG, and four lipid binding proteins (MbtK, MbtL, FadD33, and 
FadE14)(Matthew McMahon et al., 2012). 
 
Other virulence factors related to complex lipids biosynthesis in M. tuberculosis 
 The composition of surface lipids is an important feature that distinguishes 
pathogenic and non-pathogenic mycobacteria. For example, MPMs and PGLs are only 
found in pathogenic species while glycopeptidyl lipids are only produced by some 
opportunistic pathogenic species(Jeffrey Schorey and Lindsay Sweet, 2008). It is 
tempting to believe that surface lipids are one of the predominant factors among all the 
virulence effectors of the pathogenic mycobacteria, such as M. tuberculosis. Therefore, 
to better understand the survival mechanism of this notorious bacteria against the human 
immune system, it is critical for us to identify these surface lipids and elucidate their 
biosynthesis. However, our knowledge in both aspects remains at large. As discussed 
above, most PKSs found in the M. tuberculosis genome have not been attributed to the 
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synthesis of known metabolites. In addition, there are wide array of probable lipid 
binding proteins that have been shown to contribute the M. tuberculosis pathogenesis. 
They together indicate the presence of many other virulence related lipids to be 
identified, and also highlight the need to functionally characterize the proteins likely 
involved in the biosynthesis of surface lipids. At lease three categories of targets should 
be deliberately investigated in this respect. 
 First, 15 among the 25 PKSs discovered in the M. tuberculosis genome have 
been confirmed with functions in the biosynthesis of mycolate, cell wall complex lipids, 
and mycobactins, respectively, while the functions of the other 10 PKSs remain 
ambiguous. The prevailing strategy to explore the roles of PKSs is to generate the 
knock-out strains followed by analyses of the change in lipid composition. This method 
has provided valuable insights as well as some biased outputs. The challenge of the 
method lies in the complicated cellular activities associated with many unknown 
regulation mechanisms. For example, pks12 was once linked to the synthesis of PDIMs 
as the gene deletion caused deficient PDIMs in the cell wall(Tatiana Sirakova et al., 
2003). However, explicit biochemical demonstration later on amended the true function 
of PKS12 as a mycoketide synthase(Tarun Chopra et al., 2008), though its regulatory 
role in PDIM production is still mysterious. In addition to the in vivo approach, 
structural and biochemical characterization has shown potential to imply the function of 
a PKS. It is exemplified by the studies on M. tuberculosis PKS11(Kuppan Gokulan et 
al., 2013). When expressed by M. smegmatis, a soil organism closely related to M. 
tuberculosis, PKS11 is naturally bound to palmitic acid which is likely to be the 
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biological substrate. A more revealing observation is that the addition of malonyl-CoA 
and methylmalonyl-CoA leads to the formation of methylbranched alkylpyrone (Figure 
1-7) which is bound at the active site of PKS11, clearly evidenced by both X-ray 
structure and mass spectra. Though there is no reported isolation of methylbranched 
alkylpyrones from M. tuberculosis, the studies of PKS11 has strongly indicated the 
presence of such lipids. Moreover, it proves the hypothesis that versatile lipids still 
remain to be identified and functional characterization of the enzymes related to lipid 
metabolism is highly applicable to address the issue. 
 
 
Figure 1-7. Structural and biochemical characterization of M. tuberculosis PKS11 led to the 
discovery of a new type of mycobacterial complex lipids- methylbranched 
alkylpyrones(Kuppan Gokulan et al., 2013). 
 
Second, there are two NRPS containing gene clusters identified in M. 
tuberculosis(S. T. Cole et al., 1998). While one of them has been attributed to synthesize 
the peptidyl moiety of mycobactins, the function of other one, Rv0096-Rv0101 operon, is 
yet understood. Rv0096 belongs to the PE/PPE family which is a immunogenetic 
protein. Rv0097 is a putative oxidoreductase. Rv0098 is a fatty acyl-CoA 
thioesterase(Feng Wang et al., 2007a). Rv0099 (fadD10) is a lipid binding enzyme. 
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Rv0100 encodes an acyl carrier protein. Rv0101, annotated as nrp, is an NRPS which is 
highly conserved in the human pathogen M. bovis and M. leprae. While the operon is not 
required for the survival of M. tuberculosis in vitro(Christopher Sassetti et al., 2003), 
each of the genes correlates to the mycobacterial virulence(Christopher Sassetti and Eric 
Rubin, 2003; Swati Joshi et al., 2003). The precise product of the operon and its exact 
biological function are yet elucidated. In a transposon mutagenesis study, mutation of 
Mb0100 in the M. bovis BCG strain (equivalent to M. tuberculosis Rv0097) was shown 
to disrupt the biosynthesis of PDIMs and glycosylphenol-PDIMs(Grant Hotter et al., 
2005), but whether the components of the operon have a direct role in PDIM synthesis is 
uncertain. Others have argued that the product of the PPE-nrp operon would function 
via de-repressing the sigma factor SigM which further regulates synthesis of a series of 
surface lipids including PDIMs(Nisheeth Agarwal et al., 2007). Nrp shares significant 
similarity with an M. smegmatis NRPS-encoding gene mps which is involved in the 
production of glycopeptidyl lipids. However, no glycopeptidyl lipids or close analogues 
have been reported in the pathogenic mycobacteria, and hence a role of M. tuberculosis 
Nrp similar to M. smegmatis Mps has been ruled out. Yet the roles of Rv0098 and 
FadD10 in lipid metabolism suggest that the products of the operon are likely to be 
lipopeptides. We have determined the structure and function of FadD10, which shines 
light on the identification of the virulence-associated lipopeptides and the understanding 
of the biological role. These studies are discussed in CHAPTER IV. 
Third, associated with mycobacterial lipid metabolism, are a notable variety of 
lipid binding proteins, which can be exemplified by 14 transmembrane lipid transport 
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proteins (MmpLs), 36 possible fatty acyl-CoA dehydrogenases (FadEs), and 34 possible 
fatty acyl-CoA synthetases (FadDs). Surely the versatility of complex lipids necessitates 
the diversity of the supportive proteins, but such a wide array of redundancy still induces 
doubt on a rough functional classification. Indeed, the annotation of FadD enzymes has 
been amended after further investigations into individual members. M. tuberculosis 
FadDs were initially thought to be engaged in the fatty acid degradation, analogous to E. 
coli FadD(David Clark and John Cronan, 1996). Yet soon several FadDs were found 
important for the synthesis of cell wall lipids, such as FadD32 for mycolates, FadD26 for 
PDIMs, FadD23 for SLs(Tarun Chopra and Rajesh Gokhale, 2009). A series of genetic, 
biochemical, and structural analyses have then been conducted to elucidate the 
distinctive functions of M. tuberculosis FadDs, which has led to the recent discovery of 
fatty acyl-acyl carrier protein synthetase activity in some of the them(Omita Trivedi et 
al., 2004; Pooja Arora et al., 2009). These FadDs which are likely to be responsible in 
anabolism instead of metabolism have been re-annotated as fatty acyl-AMP ligases 
(FAALs). However, the new annotation is solely based on sequence similarity which has 
been proven to be a rough criteria. As elaborated in CHAPTER IV, we have found that 
FadD10, mis-annotated as fatty acyl-CoA synthetase, is indeed an FAAL to transfer fatty 
acyl chains to an acyl carrier protein (Rv0100)(Zhen Liu et al., 2013). This contradicts 
the current sequence-based paradigm for the classification of FadDs, and necessitates 
further investigations into the enzymes of the newly identified FAAL subclass. 
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CHAPTER II 
MYCOLIC ACID CYCLOPROPANATION IS ESSENTIAL FOR VIABILITY, DRUG 
RESISTANCE AND CELL WALL INTEGRITY OF MYCOBACTERIUM 
TUBERCULOSIS* 
 
Summary 
Mycobacterium tuberculosis infection remains a major global health problem 
complicated by escalating rates of antibiotic resistance. Despite the established role of 
mycolic acid cyclopropane modification in pathogenesis, the feasibility of targeting this 
enzyme family for antibiotic development is unknown. We show through genetics and 
chemical biology that mycolic acid methyltransferases are essential for M. tuberculosis 
viability, cell wall structure, and intrinsic resistance to antibiotics. The tool compound 
dioctylamine, which we show acts as a substrate mimic, directly inhibits the function of 
multiple mycolic acid methyltransferases, resulting in loss of cyclopropanation, cell 
death, loss of acid fastness, and synergistic killing with isoniazid and ciprofloxacin. 
These results demonstrate that mycolic acid methyltransferases are a promising 
antibiotic target and that a family of virulence factors can be chemically inhibited with 
effects not anticipated from studies of each individual enzyme. 
 
                                                
* This work has been published in and is reprinted with permission from: 
Daniel Barkan#, Zhen Liu #, James Sacchettini, and Michael Glickman (# equal 
contribution). “Mycolic acid cyclopropanation is essential for viability, drug resistance 
and cell wall integrity of Mycobacterium tuberculosis” Chemistry & Biology 2009, 
16(5), 499-509 Copyright 2009 (Elsevier Inc.) 
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Introduction 
Human infection with Mycobacterium tuberculosis continues to cause 
unrelenting suffering. Although infection with M. tuberculosis is a curable with 
prolonged multidrug antibiotic therapy, the drug regimens are often toxic or difficult to 
complete. In the developing world, curative therapy for M. tuberculosis is difficult to 
execute, leading to two million deaths per year worldwide(Christopher Dye, 2006). 
Infection with antibiotic-resistant M. tuberculosis is an increasing problem and requires 
more prolonged antibiotic therapy for cure(World Health Organization, 2008). In the 
case of extensively drug-resistant tuberculosis, therapy is often impossible(Neel Gandhi 
et al., 2006). This dire reality has prompted a significant worldwide effort to discover 
new drugs to treat M. tuberculosis infection. Although any new agent active against M. 
tuberculosis would be welcome, of particular interest are new drugs that would allow 
shortening of tuberculosis chemotherapy through rational targeting of gene products 
important for persistent infection. An increasing number of potential drug targets in M. 
tuberculosis are cell wall biosynthetic enzymes, including enzymes involved in mycolic 
acid biosynthesis and modification. 
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Figure 2-1. Chemical structures of the major mycolic acids of M. tuberculosis and BCG-
R. Cyclopropane rings and methyl branches are shown and annotated with the methyltransferase 
responsible for their synthesis. BCG-P lacks methoxymycolates due to a mutation in MmaA3. 
 
Mycolic acids are α-alkyl, β-hydroxy fatty acids that are produced by all 
mycobacteria and are the signature lipid of the hydrophobic mycobacterial cell wall. 
Mycolic acid biosynthesis has been intensely studied due to the unique structure of these 
lipids and their importance for tuberculosis antibiotic therapy and M. tuberculosis 
pathogenesis(Clifton Barry III et al., 1998). M. tuberculosis and Mycobacterium bovis 
produce three major mycolic acid types: alpha mycolate, methoxymycolate, and 
ketomycolate. The chemical structures of these lipids shown in Figure 2-1 were 
determined over years of exhaustive study(Clifton Barry III et al., 1998; Motoko 
Watanabe et al., 2002; Motoko Watanabe et al., 2001). Although the core mycolate 
structure is conserved among mycobacteria, only pathogenic slow growing mycobacteria 
produce significant amounts of cyclopropanated mycolic acids. Alpha mycolic acids 
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contain two cis cyclopropane rings on the meromycolate chain. Oxygenated mycolates 
contain either a distal methoxy or ketone group and a proximal cis or trans cyclopropane 
ring. The cyclopropane rings and methyl branches of these lipids are synthesized by a 
family of S-adenosyl methionine-dependent methyltransferases. The enzymes of this 
family are highly homologous both in primary sequence and tertiary structure(Chih-chin 
Huang et al., 2002). Despite this structural similarity, genetic deletion of each methyl- 
transferase in M. tuberculosis has revealed highly specific biosynthetic roles of each 
enzyme. PcaA and MmaA2 are required for alpha mycolate cyclopropanation(Michael 
Glickman, 2003; Michael Glickman et al., 2000), CmaA2 for trans cyclopropanation of 
the oxygenated mycolates(Michael Glickman et al., 2001), MmaA4 and MmaA3 for 
distal functionality of the oxygenated mycolates(Eugenie Dubnau et al., 2000; Marcel 
Behr et al., 2000), and MmaA1 for methyl branch formation preceding the 
cyclopropanation step by CmaA2 (M.S.G., unpublished data). 
M. tuberculosis strains deficient for cyclopropanation have revealed an important 
role for this lipid modification in pathogenesis. Loss of pcaA in M. tuberculosis causes 
an early growth defect in the lungs, defective persistence during late infection, and 
failure to activate macrophage innate immune responses(Michael Glickman et al., 2000; 
Vivek Rao et al., 2005). In contrast, loss of cmaA2 results in hypervirulence and 
hyperinflammatory innate immune activation in macrophages(Vivek Rao et al., 
2006)and loss of mmaA4 causes excessive IL-12 production(Dee Dao et al., 2008). 
These phenotypes are due to altered inflammatory activity of cyclopropane-deficient 
trehalose dimycolate, implicating cyclopropanation as an immunomodulatory lipid 
  29 
modification(Dee Dao et al., 2008; Vivek Rao et al., 2006; Vivek Rao et al., 2005). 
However, these results do not clearly define mycolic acid methyltransferases as an 
attractive drug target in M. tuberculosis because the consequences of complete 
cyclopropane loss are unknown and targeting of CmaA2 alone in preference to other 
methyltransferases might be deleterious to the host. 
In this study we address the suitability of mycolic acid methyltransferases as M. 
tuberculosis drug targets. We show that the mycolic acid methyltransferase enzyme 
family can be targeted by a single tool compound and that this inhibition has pleiotropic 
effects on M. tuberculosis cells, including loss of cell wall integrity and eventual cell 
death. 
 
Results 
Deletion of cmaA2 from BCG pasteur is only possible after complementation with a 
functional mmaA3 
Previous work from our laboratory and others has shown that mycolic acid 
methyltransferases are individually nonessential for growth in vitro(Dubnau et al., 1998; 
Eugenie Dubnau et al., 2000; Marcel Behr et al., 2000; Michael Glickman, 2003; 
Michael Glickman et al., 2000; Michael Glickman et al., 2001), including the trans 
cyclopropane synthase of the oxygenated mycolates CmaA2. As we have shown that 
deletion of cmaA2 from M. tuberculosis produces a hypervirulent strain(Vivek Rao et 
al., 2006), we attempted to delete this gene from BCG Pasteur (BCG-P) to study its 
effect on BCG immunogenicity. To delete cmaA2, we infected BCG-P with a 
  30 
temperature-sensitive special- ized transducing phage designed to replace the entire 
cmaA2 coding sequence with a hygromycin resistance gene. To our surprise, despite our 
prior deletion of cmaA2 from M. tuberculosis using the same technique, we were unable 
to obtain hygromycin-resistant transductants on multiple attempts (data not shown). We 
have successfully deleted multiple genes from BCG-P using specialized transduction 
(data not shown;(Hideki Makinoshima and Michael Glickman, 2005; Michael Glickman 
et al., 2000), indicating that our failure to obtain a cmaA2 knockout was not due to a 
general failure of this technique in this strain. BCG-P, along with many other BCG 
substrains, lacks methoxymycolates due to a point mutation in mmaA3, the gene 
encoding the methyltransferase that adds the methoxy group to 
methoxymycolates(Marcel Behr et al., 2000). BCG Russia (BCG-R) has a functional 
MmaA3 and therefore synthesizes methoxymycolates. We were able to delete cmaA2 
from BCG-R using the same specialized transducing phage that failed in BCG-P (Figure 
2-2 A), indicating that lack of methoxymycolates may be the factor preventing cmaA2 
deletion in BCG-P. To test this idea, we complemented BCG-P at the chromosomal attB 
site with the mmaA3 gene (BCG-P attB::mmaA3). As previously reported(Adam Belley 
et al., 2004; Dubnau et al., 1998; Marcel Behr et al., 2000), BCG-P attB::mmaA3 
synthesized methoxymycolates (Figure 2-2 B). Transduction of BCG-P attB::mmaA3 
with the cmaA2 knockout phage resulted in successful deletion of cmaA2 (Figure 2-2 C). 
To confirm that the function of cmaA2 in BCG is to synthesize trans cyclopropane rings, 
as previously shown in M. tuberculosis(Michael Glickman et al., 2001), we isolated total 
mycolic acids from the BCG attB::mmaA3 cmaA2::hyg strain and analyzed them by 
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nuclear magnetic resonance (NMR). Trans cyclopropane rings were not detected in the 
ΔcmaA2 strain, confirming that the function of CmaA2 is identical in BCG and M. 
tuberculosis. This data suggested that null mutations in mmaA3 and cmaA2 may be 
synthetically lethal for slow growing mycobacteria. 
 
 
 
Figure 2-2. Genetic analysis of mycolic acid methyltransferase synthetic phenotypes. 
(A) Southern blot showing the deletion of cmaA2 from BCG-R. Genomic DNA was cut with 
EcoRI and probed with a DNA fragment flanking cmaA2. The predicted size for wild-type is 3.8 
kb and for ΔcmaA2 is 1.8 kb. 
(B) Radio TLC from BCG-P and BCG-P attB:: mmaA3, showing the appearance of 
methoxymycolates in the complemented strain. α, alpha mycolates; m, methoxymycolates; k, 
ketomycolates. 
(C) Southern blot showing deletion of cmaA2 from BCG-P attB::mmaA3. Fragment sizes are as 
in (A). 
(D) BCG-P was complemented at the attB site with mmaA3 gene under an AHT-sensitive 
promoter and mycolic acids were analyzed from strains grown with (+AHT) and without (-AHT) 
inducer. After the deletion of cmaA2 or mmaA1 from this strain (while supplementing with 
AHT), AHT was withdrawn and mycolic acids were prepared. 
(E) Radio TLC showing the removal of mmaA3 by zeocin marker exchange. Mycolates from 
parent strains and zeocin-resis- tant transformants were analyzed by TLC. 
(F) Growth curve (represented as OD600 measure- ments) at 32.5°C of BCG-P (u), BCG-P 
ΔcmaA2 (MGM1919;n), BCG-R (▴), and BCG-R ΔcmaA2 (MGM295; ▾). 
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To further confirm synthetic lethality, we created an mmaA3 depletion strain that 
expressed mmaA3 from a tetracycline- inducible promoter. This strain displayed 
anhydrotetracycline (AHT)-dependent synthesis of methoxymycolates (Figure 2-2 D, 
left). Using specialized transduction, cmaA2 and mmaA1 were deleted from this strain in 
the presence of AHT. Southern blotting confirmed successful deletion of cmaA2 and 
mmaA1 (data not shown) and NMR of total mycolic acids from these strains confirmed 
lack of trans cyclopropane rings. To our surprise, depletion of mmaA3 by AHT 
withdrawal did not result in cell death (data not shown). Examination of these strains 
revealed minimal methoxymycolate production without AHT (Figure 2-2 D, right), 
ruling out constitutive expression of mmaA3 due to a mutation in the tetracycline 
repressor. This result could indicate that mmaA3/mmaA1 and mmaA3/cmaA2 are not 
synthetically lethal. However, the tetracycline regulation is somewhat leaky, which 
could allow survival due to the low-level methoxymycolate production that is visible in 
Figure 2-2 D. To completely remove the mmaA3 cassette from the ΔmmaA1 and 
ΔcmaA2 strains, we used marker exchange(Carey Pashley and Tanya Parish, 2003). A 
zeocin marked vector replaced the mmaA3 cassette after transformation and the resulting 
zeocin-resistant transformants lacked methoxymycolates (Figure 2-2 E), indicating that 
sequential deletion of cmaA2/mmaA3 or mmaA1/mmaA3 is possible. Taken together, one 
interpretation of these genetic studies is that compensatory changes in membrane fluidity 
in the tetracycline depletion and zeocin strains allowed isolation of the double mutants, 
possibly due to the order in which the genes were deleted. To test whether the 
cmaA2/mmaA3 double mutants have alterations in membrane fluidity that would support 
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this model, we grew these strains in low temperature. We found that deletion of cmaA2 
from BCG-R moderately impaired growth at 32° (Figure 2-2 F). Strikingly, BCG-P grew 
poorly at 32° and inactivation of cmaA2 in BCG-P abolished growth (Figure 2-2 F). 
These findings support the genetic data indicating that loss of cmaA2/ mmaA3 impairs 
viability due to alteration in membrane fluidity. 
 
Dioctylamine inhibits multiple pathways of mycolic acid modification 
To investigate the phenotypic consequences caused by loss of mycolic acid 
modification, we sought a chemical inhibitor of these enzymes. Dioctylamine was 
recently identified as an inhibitor of Escherichia coli CFAS, an enzyme that 
cyclopropanates the membrane fatty acids of E. coli(Dennis Grogan and John Cronan, 
1997; Dominique Guianvarc'h et al., 2006). The IC50 of dioctylamine for CFAS was 4 
µM. Dioctylamine is chemically similar to didecyldimethylammonium bromide 
(DDDMAB), which we have previously crystallized in the active site of CmaA2(Chih-
chin Huang et al., 2002) (see Figure 2- 3A for structures), suggesting that dioctylamine 
might also inhibit mycolic acid methyltransferases by acting as a substrate mimic. To 
test whether dioctylamine is an inhibitor of cyclopropanation, we grew BCG-R (which 
has a mycolic acid profile highly similar to that of M. tuberculosis) with 14C acetic acid 
and in escalating concentrations of dioctylamine ranging from 0.125 to 10 µM or vehicle 
control. After 6 hr, 14C -labeled mycolic acid methyl esters were prepared and analyzed 
by radio thin layer chromatography (TLC). We observed that 2 µM dioctylamine 
completely inhibited methoxymycolate production, consistent with loss of MmaA3 
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function (see arrowhead in Figure 2-3 B). 
 
 
 
Figure 2-3. Dioctylamine inhibits multiple pathways of mycolic acid modification. 
(A) Chemical structures of dioctylamine and DDDMAB. DDDMAB was previously identified in 
the active site of crystals of CmaA2. 
(B) One-dimensional TLC of mycolates isolated from BCG-R treated with the concentration of 
dioctylamine (µM) indicated under each lane. Alpha mycolate (α), methoxymycolate (m), and 
ketomycolate (k) are indicated at the left edge. The arrowhead marks the position of 
methoxymycolate, which is absent from the 2 µM sample. The arrow marks hydroxymycolate. 
(C) Two-dimensional Argentation TLC of BCG-R treated with 0.5 µM dioctylamine. The 
sample was separated without silver (dimension 1) and then with silver (dimension 2). The silver 
dimension retards lipids on the basis of unsaturation. Two unsaturated derivatives of alpha 
mycolate are visible, as well as unsaturated ketomycolates and methoxymycolates (arrowhead). 
(D and E) Two-dimensional Argentation TLC of BCG-R treated with 2 µM (D) and 10 µM (E) 
dioctylamine. Unsaturated derivatives of the alpha mycolates and ketomycolates are marked with 
arrowheads, as are the positions of mature alpha mycolate (α), ketomycolate (k), and 
hydroxymycolate (hy). 
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In addition, treatment with 4 and 10 µM dioctylamine caused accumulation of a 
mycolic acid migrating slower than ketomycolate (see arrow in Figure 2-3 B), consistent 
with the previously reported hydroxymycolate that accumulates in the absence of 
functional MmaA3(Annaik Quemard et al., 1997). This polar lipid migrated slower than 
authentic epoxymycolate from Mycobacterium smegmatis (data not shown), confirming 
its likely identity as hydroxymycolate. At 10 µM, there is substantial but incomplete 
inhibition of ketomycolate biosynthesis (compare 0.125 to 10 µM in Figure 2-3 B). The 
observed mycolic acid profiles with dioctylamine treatment are consistent with loss of 
MmaA3 and MmaA4 function, suggesting that dioctylamine inhibits these enzymes. 
 Whereas inhibition of MmaA3 and MmaA4 leads to loss of an entire mycolate 
class and is therefore easily detected on one-dimensional TLC, chemical inhibition of 
other cyclopropane synthases produces unsaturated lipids that are identical in polarity to 
their parent lipids and therefore not detectable on one-dimensional TLC. This phenotype 
was previously demonstrated in M. tuberculosis strains lacking the mycolic acid 
cyclopropane synthases PcaA, MmaA2, and CmaA2(Michael Glickman, 2003; Michael 
Glickman et al., 2000; Michael Glickman et al., 2001). To test the inhibition of these 
enzymes by dioctylamine, we performed two-dimensional argentation TLC on mycolic 
acids isolated from dioctylamine-treated BCG-R. In this technique, lipids are first 
separated by polarity and then by degree of any type of unsaturation in the second 
(silver) dimension. After treatment of BCG-R with 0.5 µM dioctylamine, we observed 
two unsaturated derivatives of the alpha mycolate, consistent with inhibition of alpha 
mycolate cyclopropanation (Figure 2-3 C, arrow- head to the left of mature alpha). We 
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also observed unsaturated derivatives of methoxymycolates and ketomycolates, 
consistent with impaired cyclopropanation of the proximal position of these lipids 
(Figure 2-3 C). Cells treated with 2 mM dioctylamine produced no mature alpha 
mycolate and two species of unsaturated alpha mycolate, the more abundant of which 
was more fully retarded (arrowheads in Figure 2-3 D). The ketomycolate appeared as 
three species, mature keto and two unsaturated species, likely cis and trans unsaturated. 
At 10 µM, almost no mature ketomycolate was observed (Figure 2-3 E). These data 
strongly indicate that dioctylamine is a dose-dependent inhibitor of multiple mycolic 
acid methyltransferases. These TLC data, combined with extensive prior genetic 
characterization of mycolic acid modifications, indicate that dioctylamine inhibits the 
lipid modifications performed by MmaA4, MmaA3, PcaA, MmaA2, and CmaA2. 
 
Mycolic acid methyltransferases are direct targets of dioctylamine 
The data presented above strongly indicate that dioctylamine inhibits multiple 
pathways of mycolic acid cyclopropanation and methylation. However, this effect could 
be due to direct inhibition of mycolic acid methyltransferase enzymes or an indirect 
effect. To prove that the methyltrasferases are direct dioctylamine targets, we 
overexpressed hemagglutinin-tagged versions of MmaA1, MmaA3, CmaA2, PcaA, 
MmaA2, and MmaA4 on a multicopy episomal plasmid and tested the effect on 
dioctylamine sensitivity. 
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Figure 2-4. Mycolic acid methyltransferases are direct targets of dioctylamine. 
(A) Wild-type BCG-R (plus empty vector) or BCG-R carrying a multicopy plasmid expressing 
MmaA4 (MmaA4 OE) were treated with vehicle (left lanes) or dioctylamine (right lanes) and 
radiolabeled mycolic acids were analyzed by TLC. 
(B) Wild-type BCG-R (plus empty vector) (top panel) or BCG-R carrying a multicopy plasmid 
expressing CmaA2 (CmaA2 OE) (bottom panel) were treated with dioctylamine and 
radiolabeled mycolates were analyzed by two-dimensional argentation TLC. 
(C) Wild-type BCG-R (plus empty vector) (upper left) or BCG-R carrying a multicopy plasmid 
expressing PcaA (PcaA OE) (upper right) or MmaA2 (MmaA2 OE) (lower left) were treated 
with dioctylamine and radiolabeled mycolic acids were analyzed by two-dimensional argentation 
TLC. The black arrowhead indicates alpha mycolate with two double bonds and the white 
arrowhead indicates mature alpha mycolate with two cyclopropane rings. 
 
 
The expression of these proteins was confirmed by western blotting in M. 
smegmatis and BCG-R. Overexpression of MmaA4 strongly reversed the inhibition of 
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ketomycolate synthesis observed with dioctylamine (Figure 2-4 A). Similarly, 
overexpression of CmaA2 reversed the accumulation of unsaturated ketomycolates seen 
with dioctylamine treatment (Figure 2-4 B). Overexpression of MmaA2 and PcaA also 
reversed the accumulation of unsaturated alpha mycolate in dioctylamine-treated cells. 
In MmaA2-expressing cells, the predominant alpha mycolate that accumulated was fully 
saturated (white arrowhead in Figure 2-4 C), whereas in PcaA-expressing cells, the alpha 
mycolate was mixture of monounsaturated and dicyclopropanated lipids (Figure 2-4 C). 
Although diunsaturated alpha mycolate is the major lipid in dioctylamine-treated cells 
(black arrowhead in Figure 2-4 C), none of this lipid was visible in the PcaA 
overexpressor. In contrast, although the lack of methoxymycolate in dioctylamine-
treated cells is consistent with loss of MmaA3 function, overexpression of MmaA3 did 
not reverse this effect. This suggests that MmaA3 may be an indirect target of 
dioctylamine, possibly through other mycolic acid methyltransferases. 
 
Dioctylamine inhibits the methyltransferase activity of CmaA2 in vitro 
To examine the in vitro activity of M. tuberculosis mycolic acid 
methyltransferases and their inhibition of dioctylamine, we developed a new enzymatic 
colorimetric assay that detects conversion of S-adenosylhomocysteine (SAH) to 
homocysteine by SAH hydrolase (SahH) (Lozada-Ramirez et al., 2006). This assay is 
diagrammed in Figure 2-5 A. Using this assay, we screened unsaturated fatty acids, 
including oleic, nervonic, arachidonic, and cis-11,14-eicosadienoic acid as substrates of 
M. tuberculosis CmaA2. Although none of these substrates are close in structure to the 
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authentic substrate (i.e., a long chain acyl-ACP), we were able to demonstrate 
cyclopropanation of double bonds and determine kinetic parameters using a Lineweaver-
Burk plot (Figure 2-5 B). Of these, Eicosadienoic acid (Km = 16.8 µM and kcat = 0.0027 
s−1) was the best candidate to test the inhibitory effect of dioctylamine. An accurate IC50 
was not obtainable because we had to use a relatively large amount of protein (4 µM) in 
order to observe the reaction progress. However, the inhibition from dioctylamine was 
obvious as it reduced the activity of CmaA2 in a concentration-dependent manner 
(Figure 2-5 C). When 2 µM dioctylamine was added to the reaction, the rate was reduced 
by 50%, indicating a fairly potent inhibition against the enzyme and consistency with 
dioctylamine inhibition of the cyclopropane fatty acid synthase from E. coli. These data 
demonstrate that dioctylamine is a direct inhibitor of mycolic acid methyltransferases. 
 
 
A 
 
Figure 2-5. Dioctylamine inhibits CmaA2 in vitro. (A) Scheme of the enzymetic assays for M. tb 
CMASs. DTNB, dithiobis-(2-nitrobenzoic acid); TNB, 2- nitro-5-thiobenzoic acid. (B) 
Lineweaver–Burk plot using eicosadienoic acid as substrate. (C) The in vitro inhibitory action of 
dioctylamine on CmaA2 activity. 
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Figure 2-5 continued. 
 
The structure of CmaA2 with bound dioctylamine reveals the molecular basis for activity 
To further demonstrate that dioctylamine is a direct inhibitor of mycolic acid 
methyltransfer and explore the molecular basis for its activity, we solved the structure of 
the CmaA2 protein in complex with the compound. The structure was solved by 
molecular replacement at 2.67 Å resolution (Table 2-1). The overall fold is largely 
similar to the previously reported structure of CmaA2 complexed with DDDMAB and 
SAH (PDB code 1KPI)(Chih-chin Huang et al., 2002), showing an rmsd of 0.315 Å after 
superimposition (Figure 2-6 A). Moreover, the lipophilic ligands in the two structures 
are similarly oriented in the binding site of the mycolic acyl substrate. Like DDDMAB, 
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dioctylamine adopts a U-shape conformation with the nitrogen pointing to the previously 
revealed SAM binding pocket and the two aliphatic chains extending to the catalytic site 
entrance. Modeling SAM into the active site by superimposing the MmaA4-SAM 
structure (PDB code 2FK8) with CmaA2-SAH and dioctylamine complex, we see the 
nitrogen of dioctylamine is approximately 3.1 Å away from the active methyl group of 
SAM, indicating that the nitrogen is situated at the position of the substrate double bond 
to be modified. Whereas the hydrophobic binding pocket binds the aliphatic chains of 
DDDMAB and dioctylamine similarly, the ammonium or amine nitrogens differ 
substantially in their interaction with the protein (Figure 2-6 B). For both of the species, 
the residues within 5 Å distance from nitrogen include Tyr24, Tyr41, Gly145, Glu148, 
and Tyr247. Tyr41 stabilizes the ammonium of DDDMAB through cation-π interaction. 
In contrast, when dioctylamine binds to the same site, its nitrogen drifts 0.5 Å away from 
the face of Tyr41. Gly145 tilts toward the nitrogen at the same time, with its backbone 
oxygen forming a van der Waals interaction with the nitrogen atom at a 3.2 Å distance. 
This distance is 4.0 Å in the structure in complex with DDDMAB, which is likely the 
result of the steric repulsion from the two methyl groups of the ammonium. Thus, this 
structural analysis of the dioctylamine-CmaA2 interaction predicts that amine-based 
inhibitors of these will be more potent than ammonium-based inhibitors. 
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Table 2-1. Data collection and refinement statistics for CmaA2 in complex with dioctylamine. 
Data collection 
Space group I4122 
Unit cell dimensions (Å) a = b = 106.86 c = 224.98 
Molecules/asymmetric unit 1 
Wavelength (Å) 0.9795 
Resolution (Å) 50−2.68 
Completeness (%)1 99.7 (98.1) 
No. of reflections 287,172 
I/σI1 20.1 (1.62) 
Rsym1 0.0413 (0.76) 
Refinement statistics 
Resolution (Å2) 38.74−2.68 
No. of reflection work 18,719 
No. of protein atoms 2,380 
No. of water molecules 41 
No. of heteroatoms 21 
Rcryst (%) 22.29 
Rfree (%) 24.30 
Rmsd bond lengths (Å) 0.012 
Rmsd angles (Å) 1.157 
Mean temperature factor (Å2) 61.33 
1. Numbers in parenthesis indicate data for highest-resolution shell. 
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Figure 2-6. Structures of M. tuberculosis CmaA2 in complex with dioctylamine and 
DDDMAB/SAH. 
(A) The α-Carbon traces and ligands of the two structures are shown with dioctylamine colored 
pink and DDMAB/SAH colored green. The two structures show similar overall folding. All the 
ligands including bicarbonate are represented as ball and stick. The surface of the protein is 
shown with transparency. 
(B) Stereo diagram of the active site residues in proximity to dioctylamine or DDDMAB 
nitrogens. Dioctylamine and the cognate bicarbonate are represented as ball and stick, while 
DDDMAB and the cognate bicarbonate are represented as stick. The specific van der Waals 
interaction between the backbone oxygen of Gly145 and the nitrogen of dioctylamine is shown 
as dotted line. 
 
Dioctylamine is a growth inhibitor of BCG and M. tuberculosis 
To test the hypothesis that simultaneous inhibition of multiple mycolic acid 
methyltransferases is lethal to mycobacteria, we grew BCG-R and M. tuberculosis 
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Erdman in 7H9 media or 7H10 plates supplemented with different concentrations of 
dioctylamine. We found that M. tuberculosis growth was partially inhibited by 4 µM and 
completely inhibited by a 6 µM (Figure 2-7 A). Similar results were obtained with M. 
tuberculosis grown on solid media containing dioctylamine (Figure 2-7 B) and with 
BCG-R in liquid and solid media (data not shown). We did find that there was a 
considerable inoculum effect, and at higher inoculums the inhibitory effect was seen at 
higher concentrations of dioctylamine (data not shown). As the growth inhibitory 
concentration of dioctylamine is similar to the concentration active against mycolic acid 
methyltransferases, this data, coupled with the genetic data presented above, strongly 
suggest that mycolic acid modification may be an essential function for slow growing 
mycobacteria. 
To further substantiate that growth inhibition effect of dioctylamine on 
mycobacteria is indeed related to its effect on cyclopropanation, we used another tool 
compound, hexadecyltrimethylammonium bromide (CTAB). This compound, which has 
some detergent properties, was previously found to crystallize in the active site of 
CmaA1 and shares an ammonium head group similar to DDMABB, suggesting that it 
should be a weaker inhibitor than dioctylamine if growth inhibition is attributable to 
binding to mycolic acid methyltransferases. Consistent with this structure-activity 
prediction, we found CTAB to be 5-fold less active than dioctylamine in inhibiting 
mycobacterial growth (Figure 2-7 C). CTAB was also approximately 5-fold less active 
than dioctylamine in inhibiting methoxymycolate synthesis in vivo (Figure 2-7 D). 
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Figure 2-7. Dioctylamine inhibits growth of M. tuberculosis 
(A) M. tuberculosis Erdman was grown in 7H9 media, supplemented with 0 (vehicle)(●), 2 (■), 
4 (▴), and 6 µM (▾) dioctylamine. OD600 measurements were taken daily. A representative 
experiment out of five is shown. 
(B) M. tuberculosis Erdman was grown on 7H10 plates, impregnated with 0, 4, or 10 µM 
dioctylamine. The plates were kept at 37°C with 5% CO2 for 4 weeks. 
(C) BCG-R was grown in the indicated concentrations of CTAB and bacterial growth was 
measured by OD. 
(D) Radiolabeled mycolic acids from BCG-R treated with the indicated concentrations of CTAB 
(µM) were separated by one-dimensional TLC. 
(E) BCG-R overexpressing six methyltransferases (MmaA1-4, PcaA, and CmaA2) (MGM1950) 
is more resistant to dioctylamine than BCG-R with vector alone (MGM1910). A representative 
experiment out of four is shown. 
(F) The ratio of growth in the presence of dioctylamine to without dioctylamine at the 192 hr 
time point from the experiment in (E). 
 
To further demonstrate that inhibition of growth by dioctylamine is the direct 
result of inhibition of multiple mycolic acid methyltransferases, we overexpressed these 
enzymes and tested for resistance to dioctylamine. None of the strains overexpressing a 
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single enzyme (either MmaA1, MmaA2, MmaA3, MmaA4, CmaA2, or PcaA) were 
resistant to dioctylamine (data not shown), which is consistent with the nonessentiality 
of these gene products in prior genetic experiments. We then overexpressed 
simultaneously, from a single plasmid, six different enzymes of this family: MmaA1, 
MmaA2, MmaA3, MmaA4, CmaA2, and PcaA. The strain overexpressing these six 
enzymes (mgm1950) grew three times as fast as the control strain (mgm1910) in 6.5 µM 
dioctylamine, indicating partial resistance (Figure 2-7 E and Figure 2-7 F). This data 
indicates that dioctylamine kills M. tuberculosis by inhibiting multiple 
methyltransferases. 
 
Mycolic acid modification is required for acid fastness and intrinsic resistance to 
antibiotics 
The activity of dioctylamine against mycolic acid methyltransferases allowed us 
to probe the physiologic function of this unique lipid modification in a way not possible 
using the previously isolated single gene mutants or, as in prior studies, using 
overexpression of individual enzymes(Ying Yuan et al., 1998). To test whether 
cyclopropanation contributes to antibiotic resistance, we tested sublethal concentrations 
of dioctylamine in combination with sublethal concentrations of isoniazid (INH), 
ciprofloxacin, and kanamycin. We found strong synergy between dioctylamine and both 
INH and ciprofloxacin (Figures 2-8 A and B), but no synergy with kanamycin (data not 
shown). To show that this synergy is related to increased drug penetration in 
dioctylamine-treated cells, we measured the uptake of radiolabeled ciprofloxacin in 
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bacteria treated with 4 µM dioctylamine. We found a significant increase in 
ciprofloxacin penetration into dioctylamine-treated cells, an effect that was most evident 
after 5 min, but was sustained after 40 min (Figures 2-8 C). These results suggest that 
the mechanism of synergy between these two antibiotics facilitated uptake of 
ciprofloxacin by dioctylamine's effects on the mycobacterial membrane. A similar 
mechanism may explain synergy between INH and dioctylamine, although it is possible 
that the INH synergy is also a result of their combined effect on mycolic acid synthesis. 
 
 
Figure 2-8. Mycolic acid methyltransferases are required for drug resistance and acid fastness of 
Mycobacteria. 
(A) BCG-R was treated with INH, dioctylamine (Dio), or both at the indicated concentrations 
and growth was measured by OD at 600 nm. 
(B) BCG-R was treated with ciprofloxacin (Cipro), dioctylamine (Dio), or both at the indicated 
concentrations and growth was measured by OD at 600 nm. 
(C) Accumulation of 14C ciprofloxacin in untreated (white bar) or dioctylamine treated (4 µM; 
black bar) at the indicated time points after 14C ciprofloxacin addition. The y axis is counts per 
minute. 
(D) Untreated or dioctylamine (4µM)-treated cells were examined by acid fast staining using the 
modified Kinyoun technique. 
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Acid fastness of mycobacteria, a hallmark of this genus, is thought to reflect the 
hydrophobicity and structure of mycolic acids in the cell wall. This idea is supported by 
prior findings that M. tuberculosis lacking kasB display both loss of acid fastness and 
attenuation(Apoorva Bhatt et al., 2007). We tested the effect of 4 µM dioctylamine on 
the acid fastness of BCG-R and found that most of the bacteria lost their acid fastness 
(Figure 2-8 D), despite only partial growth inhibition. 
 
Discussion 
Cyclopropanation is a common membrane modification in bacteria and 
plants(Dennis Grogan and John Cronan, 1997; Xiaoming Bao et al., 2002). In most 
cases, the physiologic function of cyclopropanation is poorly defined, although 
cyclopropanation clearly has substantial effects on membrane fluidity in model 
systems(James McGarrity and John Armstrong, 1981; Nagamachi et al., 1991). 
Pathogenic mycobacteria have an extensive set of cyclopropane modifications that 
decorate the signature lipid of the mycobacterial cell wall, the mycolic acid. Recent 
studies have strongly implicated mycolic acid cyclopropanation in M. tuberculosis 
pathogenesis through its effect on the immunomodulatory properties of trehalose 
dimycolate(Vivek Rao et al., 2006; Vivek Rao et al., 2005). However, these studies did 
not clearly establish mycolic acid methyltransferases as an attractive drug target. Here 
we demonstrate that chemical inhibition of multiple mycolic acid methyltransferases is 
lethal to mycobacteria and causes pleiotropic alterations in cell envelope structure and 
drug susceptibility. These studies provide strong scientific basis for targeting mycolic 
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acid cyclopropanation as an antibiotic strategy against M. tuberculosis. 
Our findings also reveal novel physiologic roles of cyclopropanation in 
mycobacteria. Although some prior studies have indicated a role for cyclopropanation in 
membrane fluidity and permeability(Kathleen George et al., 1995; Ying Yuan et al., 
1998), the exact role of cyclopropanation in the physiology of pathogenic mycobacteria 
was unclear. A prior study indicated that the antitubercular thiacetazone may affect 
cyclopropanation, but this study concluded that the growth inhibitory effect of this drug 
was unrelated to its effect on cyclopropanation(Anuradha Alahari et al., 2007). This 
conclusion was based on the difference between the minimum inhibitory concentration 
of thiacetazone and the concentration required to affect cyclopropanation. In a more 
recent paper, the authors show that MmaA4 is required for activity of thiacetazone and 
that deletion of mmaA4 confers resistance, rather than hypersensitivity, to the 
drug(Anuradha Alahari et al., 2009). Using dioctylamine as a tool compound, we 
suggest that pharmacologic inhibition of this enzyme class causes loss of viability, a 
novel and unanticipated finding. Our finding that mycolic acid methyltransferases are 
essential for viability suggests an unanticipated role for mycolic acid modification in 
some essential cellular process. The most likely cause of this essentiality is lethal 
dysregulation of membrane fluidity leading to impaired protein localization or cell 
division. Although an off-target effect of dioctylamine causing cell death is possible, we 
believe this is unlikely because: (1) cell death is observed at the same concentration 
required to inhibit multiple methyltransferases in vivo; (2) overexpression of multiple 
enzymes can partially reverse the growth defect; (3) the structure of CmaA2 protein with 
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dioctylamine both reveals that this enzyme is a direct target and that dioctylaimine is 
acting as a substrate mimic rather than a general SAM antagonist. This makes 
nonspecific inhibition of other SAM-dependent methyltransferases (such as DNA 
methyltransferases) with nonlipid substrates unlikely. The essential physiologic role of 
mycolic acid methyltransferases is an area of interest that will be the subject of future 
investigations. 
Although dioctylamine is unlikely to be a useful antimicrobial due to host 
toxicity (data not shown), our data provide strong support for targeting mycolic acid 
methyltransferases for inhibitor development and provides a structural framework for 
optimizing active site binding through structure guided design. The structures of CmaA2 
reveal different binding determinants for ammonium or amine-based inhibitors. The 
ammonium ion mimics the carbocation intermediate of the cyclopropanation reaction 
and is stabilized by cation-π interaction. In contrast, through mimicking an electron-
donating double bond, the amine nitrogen atom of dioctylamine forms a van der Waals 
interaction with Gly145. This interaction will not occur in a mycolate substrate and 
provides a structural explanation for the successful competition of dioctylamine with the 
natural mycolate substrates. Moreover, this interaction may contribute more than cation-
π interaction to enhancing inhibitor binding, evident from our finding that acylamine 
compounds are more potent than ammonium compounds (CTAB) at inhibiting 
cyclopropanation. This indicates that amine-based inhibitors may serve as a template for 
further drug development. 
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Experimental Procedures 
Bacterial strains and growth conditions 
M. smegmatis mc2155 was grown in 7H9 liquid media supplemented with 0.05% 
Tween 80, 0.5% glycerol, and 0.5% dextrose. BCG-R (kindly provided by M. Behr), 
BCG-P, and M. tuberculosis Erdman were grown in 7H9 media supplemented with 
0.05% Tween 80, 0.5% glycerol, and 10% OADC (for M. tuberculosis) or ADS (for 
BCG). Growth on plates was done on 7H10 plates supplemented with glycerol and 
OADC or ADS at the same concentrations. 
Growth in 7H9 media was monitored by optical density (OD) at 600 nM 
measurement. Antibiotic concentrations were 20 µg/ml for kanamycin, 50 µg/ml for 
hygromycin, and 12.5 µg/ml for zeocin. 
 
Construction of mutant strains 
Deletion of mmaA1 and cmaA2 was done as described previously(Hideki 
Makinoshima and Michael Glickman, 2005; Michael Glickman et al., 2001). Briefly, a 
temperature-sensitive mycobacteriophage (phAE87) was used to introduce a 
hygromycin-resistance cassette interrupting the candidate gene at 39°C. The bacteria 
were plated on 7H10 plates with hygromycin. The resulting colonies were analyzed by 
southern blotting using a probe flanking the gene of interest. Removal of mmaA3 
previously introduced via the attB site on the pMV306kan plasmid (marker exchange) 
was done be electroporating a pMV306zeo (pMV306kan with a zeocin-R cassette 
replacing the kanamycin-R) and plating the bacteria on plates supplemented with zeocin. 
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 Mycolic acid preparation and analysis 
Mycobacteria were grown in 7H9 media to an OD600 of 0.3–0.5 in a volume of 
50–200 ml. 14C-labeled acetic acid was added to the media at a concentration of 
1µCi/ml, and the bacteria were allowed to grow for 6 hr (in the presence of 
dioctylamine) or 24 hr (without dioctylamine) more. The bacteria were harvested, and 
mycolic acids were extracted as previously described(Michael Glickman et al., 2001). 
Single dimension separation of mycolic acid classes was done on a normal phase silica 
gel HPTLC plate (Analtech) and run in a 95:5 mixture of hexanes/ethyl acetate for five 
to six developments. Two-dimensional separation was done by immersing 90% of the 
TLC plate in 10% silver nitrate, activating at 130°C for 20 min, running the sample along 
the line with no silver nitrate (first dimension), rotating the TLC plate 90°, and running 
for five to six additional developments into the silver nitrate impregnated area. After 
completion, autoradiograms were developed using a Kodak BioMax Transcreen LE 
intensifying screen at 80C. NMR analysis was done as previously described(Michael 
Glickman et al., 2001). Bacteria were grown to an OD600 of 0.8, in a volume of 400–500 
ml. Bacteria were harvested and mycolic acids were prepared as before and resuspended 
in d-chloroform for the NMR analysis. 
 
Radiolabeled ciprofloxacin permeability 
14C-ciproflixacin (15 mCi/mmol) was purchased from Moravek biochemicals. 
Permeability testing was done as described previously(Jacqueline Chevalier et al., 2000; 
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Jun Liu et al., 1996). Fifty milliliters total volume of BCG-R was grown with or without 
4 mM dioctylamine to an OD600 of 0.5. The cells were concentrated and resuspended in 
1 ml to 1.5*1010cfu/ml and left to rotate at 8 rpm at 37°C for 45 min. Carbonyl cyanide 
3-chlorophenyl hydrazone (Sigma-Aldrich) was added to a final concentration of 0.1 
mM for 30 min, 14C -ciprofloxacin was added to a concentration of 25 µM, and cells 
were left rotating at 37°C. Samples of 200 µl were removed at 5, 20, and 40 min. Each 
sample was washed five times with PBS, filtered through a 0.45 µm GF/C filter on a 
Unifilter-96 plate (Perkin-Elmer), washed again, and left to dry overnight. Radioactivity 
was measured by scintillation reader (Packard). 
 
Production of M. tuberculosis CmaA2 
Cloning, protein expression, and purification of CmaA2 were performed 
similarly as previously reported(Chih-chin Huang et al., 2002), except that a modified 
pET28b vector was used to incorporate TEV cleavage sequence right ahead of the N-
terminus of the protein. The protease TEV was consequently used to remove the His6 
tag. 
 
Crystallization and data collection 
2 mg mL-1 CmaA2 in 25 mM Tris-HCl (pH 8.0) was incubated in ice with 50 
mM dioctylamine for 20 min. The protein was then concentrated to 10 mg mL-1 and 
crystallized at 18°C by hanging drop vapor diffusion. Each drop contained an equal 
volume of the protein solution and reservoir solution (2 M ammonium sulfate and 0.1 M 
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CAPS [pH 9.0]). The crystal of binary CmaA2 was flash- frozen in liquid nitrogen using 
cryoprotectant paratone. The diffraction data were collected at beamline 19-ID at the 
Advanced Photon Source, Argonne National Laboratory, and then was processed and 
reduced using HKL2000(Zbyszek Otwinowski and Wladek Minor, 1997). 
 
Structure determination and model refinement 
The structure of CmaA2 was solved by molecular replacement using 
Molrep(Alexei Vagin and Alexei Teplyakov, 1997) in CCP4. CmaA2-SAH-DDDMAB 
(PDB code 1KPI) with all nonprotein molecules removed, was used as the search model. 
The crystal was in a space group of I422. There was one protein molecule in each unit 
cell with dimensions of a = b = 106.86 Å, c = 224.98 Å , and a = b = c = 90°. A single 
solution for the molecular replacement was obtained. After rigid-body and restrain 
refinement by Refmac5(Murshudov et al., 1997) in CCP4, the Rcryst and Rfree were 24.6% 
and 26.8%, respectively. These values were reduced to 23.5% and 26.0% once 
dioctylamine and bicarbonate ion were manually built in the model by examining the Fo 
- Fc map in XtalView (McRee, 1999). The final model containing residues 9–302 as 
well as 41 water molecules was obtained after further cycles of model building and 
PHENIX refinement(Afonine et al., 2005) yielding R factors of 22.3% and 24.3%. The 
full crystallization statistics are given in Table 2-1. 
 
Enzymatic assay for CmaA2 
M. tuberculosis sahH (Rv3248c) was amplified by PCR, cloned into pET15b 
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vector, and then transformed into Novagen BL21(DE3) cells. The cells were cultured at 
37° till OD600 reached ~ 0.8. Then 1 mM IPTG was added to induce protein expression 
for 20 hours at 18°. After purified by Ni column, the protein was made apo-form by 
ammonium sulfate precipitation, and then dissolved in 20 mM phosphate buffer with pH 
= 7.5. 
All assays were performed in the presence of a 100 mM (pH 7.5) phosphate 
buffer. Twenty-five micromoles of SahH, 250 µM NAD, and unsaturated fatty acid were 
preequilibrated for more than 5 min. After 400 µM DTNB was added, the solution was 
blanked and added to preincubated 4 µM CmaA2/100 µM SAM to start the reaction. To 
examine the inhibition by dioctylamine, the dioctylamine/DMSO solution was added 
together with DTNB to the reaction mixture containing 20 µM cis-11,14-eicosadienoic 
acid. 
 
Additional Unpublished Results 
Dioctylamine binds to CmaA2 in vitro 
Analyses of known CMASs structures reveal the presence of a few tryptophans 
and tyrosines in the vicinity of active site, allowing us to use fluorescence quenching 
assay to determine the binding affinity of dioctylamine. The total fluorescence and 
specific tryptophan fluorescence were monitored at excitation wavelength of 279 nm 
(Figure 2-9 A) and 295 nm, respectively, for both CmaA2 and MmaA4 (data not shown). 
Titration of dioctylamine induced a more significant fluorescence change of CmaA2 
than that of MmaA4 at either wavelength, indicating a higher affinity of the compound 
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to the former. Indeed the manner of fluorescence decrease of MmaA4 suggests it likely 
to be caused by nonspecific interaction. Further treatment of the data by both nonlinear 
regression and double reciprocal method indicate a single binding site for dioctylamine 
in CmaA2 with Kd ≅ 0.2 µM (Figure 2-9 B). 
 
A 
 
B 
 
Figure 2-9. Dioctylamine binds to CmaA2 in vitro. (A) Fluorescence titration of CmaA2 by 
dioctylamine at the excitation wavelength of 279nm. (B) Double reciprocal curve fitting is 
applied to the normalized fluorescence change of CmaA2. Filled and unfilled spots represent 
data obtained at excitation 279 nm and excitation 295 nm respectively. 
 
CmaA2 + Dioctylamine Ex@279nm
0
200
400
600
800
250 450wavelength
i
n
t
e
n
s
i
t
y
1.5 uM CmaA2 0.1 uM DOA 0.2 uM DOA 0.3 uM DOA 0.4 uM DOA 0.6 uM DOA
0.8 uM DOA 1.1 uM DOA 1.5 uM DOA 2.0 uM DOA 2.5 uM DOA
  57 
Fragment-based screening of ligands for CmaA2 
 In search for chemical scaffolds and pharmacophores that can bind to the 
CMASs, we have applied the fragment-based drug design approach. First, the selected 
compounds are screened in a high-throughput manner using differential scanning 
fluorimetry (DSF), a technique particularly efficient in identifying low-molecular-weight 
ligands that bind to a target protein (Figure 2-10 A)(Frank Niesen et al., 2007). Second, 
saturation transfer difference (STD)-NMR, a technique typically used in compensation 
to DSF in the fragment-based drug design approach (Figure 2-10 B)(Aldino Viegas et 
al., 2011; Lawrence Kuo, 2011), is carried out to verify the hits identified by DSF. A 
total of 823 compounds from Enamine Fragment Library 2012(Herman Verheij, 2006; 
Miles Congreve et al., 2003) were screened for binding to CmaA2 by DSF, which 
yielded 18 compounds that caused the melting temperature of CmaA2 to increase by 
more than 2.95°C (Table 2-2). We repurchased 8 out of the 18 hit compounds based on 
their commercial availability, and performed STD-NMR to confirm the binding for 6 of 
them (Figure 2-10 C and D, Table 2-2). These lead fragment compounds will serve for 
the design of specific and potent inhibitors against M. tuberculosis CMASs with rational 
chemical modifications guided by further structural characterizations. 
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A 
 
B 
 
 
Figure 2-10. Fragment-based screening for ligands that bind to CmaA2. 
(A) Schematic diagram of DSF(Frank Niesen et al., 2007). The solid and dashed curves 
represent the dissociation curves of a target protein in the absence and presence, respectively, of 
a ligand. The molecules of SYPRO Orange dye are shown as orange particles. 
(B) Schematic diagram of STD-NMR(Aldino Viegas et al., 2011). 
(C) The example of typical fluorimetry obtained for a hit compound identified by DSF. 
(D) The example of typical spectra obtained for a hit compound verified by STD-NMR. The 
assignment of the peaks is marked with the same-color arrows. 
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Table 2-2. Lead fragments identified by DSF followed by STD-NMR. 
Hit compounds identified by DSF ΔTm (°C) Repurchased 
Confirmed binding by 
STD-NMR 
 
5.4 YES YES 
 
C 
 
D 
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Table 2-2 continued. 
Hit compounds identified by DSF ΔTm (°C) Repurchased 
Confirmed binding by 
STD-NMR 
 
5.4 YES NO 
 
5.0 YES YES 
 
5.0   
 
4.9 YES YES 
 
4.9 YES YES 
 
4.85   
 
4.4 YES NO 
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Table 2-2 continued. 
Hit compounds identified by DSF ΔTm (°C) Repurchased 
Confirmed binding by 
STD-NMR 
 
4.35   
 
4.35   
 
4.05   
 
3.85   
 
3.85   
 
3.35   
  62 
Table 2-2 continued. 
Hit compounds identified by DSF ΔTm (°C) Repurchased 
Confirmed binding by 
STD-NMR 
 
3.40   
 
3.35 YES YES 
 
2.97   
 
2.95 YES YES  
 
Additional Unpublished Experimental Procedures 
Determination of dissociation constant by fluorescence titration 
All measurements were performed in 100 mM HEPES buffer (pH 7.5). Emission 
profiles were obtained by using excitation at either 279 nm or 295 nm, and monitoring 
emission from 250 nm to 450 nm. Maximum emission appeared at ~ 335 nm for CmaA2 
and ~ 343 nm for MmaA4. Titration experiments were carried out by adding increasing 
amount of dioctylamine/DMSO to 1.5 µM protein/HEPES buffer. Fluorescence 
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intensities were corrected for DMSO dilution. Fluorescence intensity was normalized by 
ΔF/ΔFmax, in which ΔF was the corrected fluorescence change of each titration and ΔFmax 
was the maximum change through the experiment. Assuming each protein has n 
equivalent binding sites for dioctylamine, we determined the binding affinity (Kd) and 
binding sites (n) using the fomula: ΔFmax/ΔF = n-1*Kd-1*[dioctylamine]-1 + n-1. 
 
Differential scanning fluorimetry (DSF) 
 All the experiments (20 µL) were performed in 96-well RT-PCR plated by 
Stratagene Mx3005P QPCR system. Each reaction mixture contained 10 µM CmaA2 in 
presence of 100 mM MES buffer (pH 6.5), 500 µM SAM, and 2.5* SYPRO Orange 
protein gel stain from Life Technologies. The fragments were added in an amount of 
5mM, which were later compared with the control reaction mixtures with addition of 1 
µL DMSO. 
 
Saturation transfer difference (STD)-NMR 
 All the experiments were performed on Bruker Avance III 400MHz NMR 
spectrometer. Each experiment (600µL) contained 20 µM CmaA2 in presence of 50 mM 
phosphate buffer (pH 7.5), 10% D2O, and 2 mM of the fragment compound. 
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CHAPTER III  
CRYSTALLOGRAPHIC AND MODELING STUDIES AID THE UNDERSTANDING 
OF PRODRUG MECHANISM* 
 
 
Introduction 
Isoniazid (INH) and ethionamide (ETH) have been used extensively in the first-
line and second-line treatment of TB, respectively, since 1950s. Both reagents are pro-
drugs that undergo modifications in vivo to become bactericidal adducts. Complicated by 
the involvement of intracellular activation and metabolism, the action mode of INH and 
ETH remained mysterious for a long period until late 1990s. The mechanism of the two 
pro-drugs have been gradually unraveled in the past 15 years, aided by genomic and 
biochemical studies, especially explicated by structural demonstrations at an atomic 
resolution. 
INH must first be activated by KatG, an endogenous catalase/peroxidase(Martin 
Wilming and Kai Johnsson, 1999). The mode of INH action remained unclear until an 
                                                
* Portions of this work have been published in and are reprinted with permission from: 
Feng Wang, Paras Jain, Gulcin Gulten, Zhen Liu, Yicheng Feng, Krishna Ganesula, 
Alifiya Motiwala, Thomas Ioerger, David Alland, Catherine Vilchèze, William Jacobs 
Jr. and James Sacchettini. “Mycobacterium tuberculosis dihydrofolate reductase is not a 
target relevant to the antitubercular activity of isoniazid.” Antimicrobial Agents and 
Chemotherapy 2010, 54 (9), 3776-3782 Copyright 2010 (American Society for 
Microbiology). 
And 
Catherine Vilchèze, Yossef Av-Gay, Rodgoun Attarian, Zhen Liu, Manzour H. Hazbón, 
Roberto Colangeli, Bing Chen, Weijun Liu, David Alland, James C. Sacchettini, 
William R. Jacobs Jr. “Mycothiol biosynthesis is essential for ethionamide susceptibility 
in Mycobacterium tuberculosis.” Molecular Microbiology 2008, 69 (5), 1316-1329 
Copyright 2008 (John Wiley & Sons, Inc). 
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INH-NAD adduct was identified as the bound inhibitor in the active site of InhA, the 
enoyl-acyl ACP reductase involved in long-chain fatty acid biosynthesis, by protein 
crystallography(Denise Rozwarski et al., 1998). It was hypothesized that KatG cleaves 
the hydrazide on INH to an isonicotinoyl radical, which then reacts with NAD to form 
an adduct that binds to and inhibits InhA(Graham Timmins and Vojo Deretic, 2006). 
The crystal structure of InhA bound with the adduct indicates that an isonicotinoyl 
moiety was covalently attached to the 4-position of the nicotinamide ring of NAD 
cofactor in an S configuration. The chemical structure of the INH-NAD adduct was 
found to be consistent with the molecular weight obtained by the mass analysis(Denise 
Rozwarski et al., 1998). Later studies demonstrated that INH-NAD adduct could be 
generated by a KatG-catalyzed oxidation in the presence of NAD+(Benfang Lei et al., 
2000; Martin Wilming and Kai Johnsson, 1999), which strongly inhibits InhA (Ki = 5 
nM) to block mycolic acid biosynthesis(Catherine Vilchèze et al., 2006; Denise 
Rozwarski et al., 1998; Richa Rawat et al., 2003). 
ETH, a thioamide analogue of INH, also functions via inhibiting InhA and 
subsequently the mycolate biosynthesis(Asesh Banerjee et al., 1994). Yet its activation is 
not performed by KatG as the KatG mutant strains resistant to INH remain sensitive to 
ETH(Glenn Morlock et al., 2003). Various spontaneous mutations and clinical isolates 
have indicated that the Baeyer-Villiger monooxygenase EthA is essential to activate 
ETH(Alain Baulard et al., 2000; Andrea DeBarber et al., 2000; Marco Fraaije et al., 
2004). While multiple in vitro biochemical studies failed to interpret the action of EthA 
on ETH(Andrea DeBarber et al., 2000; Tommaso Vannelli et al., 2002), a whole-cell 
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based activation strategy and the subsequent biophysical analyses have delineated the 
bioactive form of ETH(Feng Wang et al., 2007b). In this study, M. tuberculosis EthA 
and InhA are co-expressed by E. coli in presence of ETH. The following mass spectra 
and a 2.2 Å-resolution crystallography clearly show that the purified InhA is complexed 
to ethyl isonicatinoyl-NAD (ETH-NAD) in a way similar to the binding to isonicatinoyl-
NAD (INH-NAD). The isolated ETH-NAD compound exhibits potent inhibition to 
native InhA (Ki = 7 nM), which has further established itself as the bioactive metabolite 
of ETH. 
The active forms of INH and ETH have been defined, still there are 
contradictions regarding their intracellular action and metabolism. For INH, though 
“genetic and biochemical studies have provided convincing evidence that InhA is the 
primary target of INH(Amalio Telenti, 1998; Hongling Guo et al., 2006), other putative 
targets of INH have also been proposed(Graham Timmins et al., 2004; Khisimuzi Mdluli 
et al., 1998). Recently, 17 proteins other than InhA were identified from M. tuberculosis 
lysate that could tightly bind to an affinity matrix derived from INH-NADP or INH-
NAD adducts by proteomic analysis(Argyrides Argyrou et al., 2006a). Among these 
proteins, M. tuberculosis dihydrofolate reductase (DhfR) was shown to be strongly 
inhibited by an INH-NADP adduct in vitro (Kiapp = 1 nM) in a separate study(Argyrides 
Argyrou et al., 2006b). This INH-NADP adduct was synthesized by incubating INH and 
NADP+ in the presence of Mn(III) as a catalyst. The crystal structure of the complex 
indicated that an acyclic 4R INH-NADP adduct was selectively bound in the active site 
of DhfR. In addition, overexpression of dfrA in M. smegmatis caused a 2-fold increase 
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of resistance to INH compared to the wild-type(Argyrides Argyrou et al., 2006b). These 
observations were taken to suggest that M. tuberculosis DhfR is also a target of 
INH(Argyrides Argyrou et al., 2006a; Argyrides Argyrou et al., 2006b). 
For ETH, it is puzzling that its activation is only feasible in vivo, while in vitro 
incubation with EthA only resulted in a number of inactive metabolites(Alain Baulard et 
al., 2000; Andrea DeBarber et al., 2000; Marco Fraaije et al., 2004). This is consistent 
with the unusually low in vitro activity of EthA(Marco Fraaije et al., 2004), which 
suggests the presence of other cellular factors essential for the function of EthA or the 
formation of ETH-NAD. 
Understanding the prodrug action is critical for designing more potent inhibitors 
and strategies to resolve the drug resistance issues. Therefore, together with 
collaborators, we have (i) confirmed that InhA rather that DhfR is the cellular target 
responsible for the antitubercular activity of INH(Feng Wang et al., 2010); (ii) 
discovered that mycothiol is essential for ETH susceptibility in M. 
tuberculosis(Catherine Vilchèze et al., 2008). These are demonstrated by multiple 
genetic and biochemical evidence, among which structural biological has played an 
important role. To determine whether InhA or DhfR is a molecular target of INH, we 
activated the pro-drug in whole-cell based system and observed that only InhA was 
complexed with the INH-NAD adduct using X-ray crystallography. To validate the 
correlation between mycothiol and ETH susceptibility, we interpreted the rationale for 
the inactivation of mycothiol biosynthesis in the spontaneous mutants by homology 
modeling, and we also examined the effect of mycothiol on EthA activity. 
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Results and Discussion 
INH-NADP adduct formation was not observed in an E. coli-based activation system 
coexpressing katG and dhfR. 
In the previous study, a synthetic INH-NADP adduct derived from INH 
demonstrated strong inhibition of M. tuberculosis DhfR in vitro (Kiapp = 1 
nM)(Argyrides Argyrou et al., 2006b). However, the INH-NADP adduct was 
synthesized by using an inorganic catalyst, Mn(III). Thus, the yield of adduct generated 
from this approach might not truly reflect an enzyme-mediated process inside the cell. 
To better mimic the in vivo activation of INH, a cell-based activation system was 
designed to examine the KatG-catalyzed adduct formation and the inhibition of DhfR by 
the adduct. This E. coli-based activation system is similar to the one used previously to 
activate the prodrugs ETH and protionamide (PTH)(Feng Wang et al., 2007b). In this 
system, katG and dfrA were coexpressed in E. coli in the presence of INH to investigate 
whether the activated drug would inhibit DhfR. To construct this system, katG and dfrA 
were cotransformed into the E. coli BL21(DE3) strain and selected on 50 µg of 
kanamycin and carbenicillin/ml. The E. coli strain containing katG and dfrA genes was 
grown and induced in the presence and absence of INH, respectively. After the 
coexpression of both genes was confirmed by SDS-PAGE, recombinant KatG and DhfR 
proteins were readily purified. 
An enzyme assay was performed to determine the activity of purified DhfR. 
DhfR isolated from the experimental sample was found to be fully active (specific 
activity of 12 µmol mg−1 min−1) compared to the enzyme purified from expression in the 
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absence of INH. Since the acyclic 4R INH-NADP adduct is extremely potent against 
DhfR in vitro, it would tightly bind to DhfR if the adduct is indeed generated by KatG 
catalysis inside the cell. However, both the activity assay result and the mass analysis 
indicated that no detectable amount of the INH-NADP adduct had bound to DhfR. The 
coexpressed KatG from the same experimental sample was purified and assayed for its 
activity in vitro. The specific catalase activity of isolated KatG was 17 mol mg−1 min−1, a 
finding comparable to published data (21 mol mg−1 min−1)(Benfang Lei et al., 2000), 
which confirmed that the lack of the INH-NADP adduct did not result from the absence 
of KatG activity. Therefore, the acyclic 4R INH-NADP adduct is not an activated INH 
product generated by KatG catalysis inside the E. coli cell-based system. 
 
INH-NAD adduct was detected in the E. coli based activation system co-expressing katG 
and inhA. 
It has been shown that KatG activates INH and catalyzes the formation of an 
INH-NAD adduct in vitro(Graham Timmins and Vojo Deretic, 2006; Martin Wilming 
and Kai Johnsson, 1999). In order to demonstrate that this KatG-catalyzed INH-NAD 
adduct formation and its inhibition of InhA can be reproduced in the E. coli-based 
system, both katG and inhA were transformed into BL21(DE3) cells and coexpressed in 
the presence of INH. InhA was rapidly purified by a Ni-NTA affinity column, and an in 
vitro enzyme assay was performed. InhA isolated from the experimental sample had 
<15% of the specific activity of InhA purified without the addition of INH under the 
same assay condition. The bound inhibitor was isolated by denaturing the InhA purified 
  70 
from the experimental sample, and a 1 µM concentration of the inhibitor led to complete 
inhibition of native InhA. The crystal structure of InhA in complex with the inhibitor 
was solved to 2.4-Å resolution (Table 3-1). In the active site of InhA, an unbiased 
electron density map (Figure 3-1) clearly indicated the presence of a modified NAD with 
an isonicotinic-acyl group covalently attached to the 4-position of the nicotinamide ring 
in a 4S configuration, which is consistent with the previously identified INH-NAD 
adduct(Denise Rozwarski et al., 1998). This is the first time that the activation of INH by 
KatG and the formation of the INH-NAD adduct has been demonstrated in a whole-cell 
environment. This confirms that our E. coli cell-based system is capable of activating the 
pro-drug INH. 
 
 
Figure 3-1. The Fo – Fc map that is used to model the INH-NAD adduct (cyan) into the active 
site of InhA (pink). The difference map is contoured at 3 sigma level. 
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Table 3-1. Data collection and refinement statistics for InhA in complex with INH-NAD. 
Data collection 
Space group P6222 
Unit cell dimensions a=b=98.85Å, c=138.84Å 
α=β=90.0°, γ=120.0° 
Molecules/ASU 1 
Wavelength (Å) 1.542 
Resolution (Å) 50-2.44 
Completeness (%)1 99.9 (99.5) 
No. of reflections 15560 
I/σI* 41.02 (5.46) 
Rsym* 0.0157 (0.1915) 
Refinement statistics 
Resolution (Å) 26.96-2.43 
No. of reflection work 15675 
No. of protein atoms 1994 
No. of water molecules 169 
No. of heteroatoms 52 
Rcryst (%) 20.84 
Rfree (%) 25.62 
RMSD bond length (Å) 0.01 
RMSD angle (°) 1.47 
Mean temperature factor (Å2) 55.27 
*. Numbers in parenthesis indicate data for highest-resolution shell. 
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Spontaneous mutants of M. tuberculosis, co-resistant to INH and ETH, map to mshA 
 
Table 3-2. Point mutations in and deletion of mshA cause different levels of resistance to INH 
and ETH in M. tuberculosis.(Catherine Vilchèze et al., 2008) 
 
Parent 
strain 
 
Mutant 
 
mshA mutation   
 
MIC (mg/l) 
 
MIC (mg/l) 
pMV361::mshA 
 
  Nucleotide Amino acid INH ETH INH ETH 
 
H37Rv  - - 0.06 2.5 0.06 2.5 
 mc24930 a124del Stop codon 0.5 20 0.12 2.5 
 mc24931 c382t Stop codon 0.6 20 0.06 2.5 
 mc24932 c817t R273C 0.4 10 0.06 2.5 
 mc24933 g985t G299C 0.6 20 0.12 2.5 
 mc24934 c991t Stop codon 1 10 0.5 2.5 
 mc24935 g1071a G356D 1 10 0.06 2.5 
 mc24936 a1082c E361A 0.25 20 0.06 2.5 
 mc24937 c1265del Frameshift 1 10 0.25 7.5 
 mc24938 ΔmshA  0.06 > 20 0.06 2.5 
 
 Numerous studies have demonstrated that there exist strains of M. tuberculosis 
that are resistant to INH and do not have mutations in the genes associated with INH 
resistance (katG, inhA structural gene and promoter, ndh)(Amy Piatek et al., 2000; 
Hazbon et al., 2006; Rosilene Fressatti Cardoso et al., 2004; Srinivas Ramaswamy et al., 
2003; Telenti et al., 1997).To eliminate the majority of spontaneous mutants of 
M. tuberculosis that are singly resistant to INH and map to katG, we chose to isolate 
mutants that were co-resistant to INH and its structural analogue ETH. Samples of three 
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independent M. tuberculosis H37Rv cultures were plated on media containing low 
concentrations of both INH and ETH [≤ 4-fold the minimum inhibitory concentration 
(MIC)]. Seven mutants were isolated at low frequencies (1–4 × 10−8). DNA sequence 
analysis of targeted genes in these seven strains revealed the absence of mutations in the 
genes known to mediate co-resistance to INH and ETH, namely inhA (the gene or its 
promoter region) and ndh. This analysis provided the evidence that these strains 
possessed mutations that conferred INH and ETH resistance and had not been previously 
identified in M. tuberculosis. The mutants were transformed with a cosmid genomic 
library of the drug-susceptible M. tuberculosis parent. The frequency of transformation 
was extremely low for most of the mutants (less than 100 transformants per 
transformation), and only one mutant, mc24936, which had the lowest level of INH 
resistance, yielded more than 1000 transformants. The cosmid transformants were 
screened for restoration of INH and ETH susceptibility. One potential complementing 
cosmid was isolated, sequenced and shown to contain the mshA gene, a gene 
characterized as mediating the first step in the biosynthesis of mycothiol(Gerald Newton 
et al., 2006; Gerald Newton et al., 2003), a key thiol in the family of Actinomycetes 
bacteria(Newton et al., 1996). A link between mycothiol biosynthesis and resistance to 
INH and ETH had been previously established in Mycobacterium smegmatis when 
transposon mutants in mshA were found to be resistant to INH (more than 25-fold) and 
ETH (sixfold)(Gerald Newton et al., 1999; Gerald Newton et al., 2003; Mamta Rawat et 
al., 2003). Subsequent sequence analysis of mc24936 and the other mutants showed that 
all the M. tuberculosis H37Rv mutants had missense, nonsense or frameshift mutations 
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in mshA (Table 3-2). The mshA mutants had various levels of resistance to INH (2- to 
16-fold) and ETH (four- to eightfold). This is the first report that mshA mutations confer 
co-resistance to INH and ETH in M. tuberculosis. 
 
Comparison of the MshA structures of M. tuberculosis and Corynebacterium 
glutamicum establishes a rationale for the inactivation of MshA in the mutants 
The mshA mutant strains used in this study are found to be defective in the 
synthesis of mycothiol. This can be explained by that the mutations lead to the loss of 
MshA function based on our modeling studies. “Given the sequence identity (45.9%) 
between M. tuberculosis MshA and Corynebacterium glutamicum MshA (CgMshA) 
whose structure was recently determined(Matthew Vetting et al., 2008), the monomeric 
homology model of M. tuberculosis MshA was created using CPHmodels 2.0(O. Lund et 
al., 2002) with the UDP-complexed CgMshA (PDB code 3C4Q) as template. 
Superimposition of the model of M. tuberculosis MshA (consisting of Arg46–Ile445) 
and the chain B from UDP/inositol-phosphate-bound CgMshA (PDB code 3C4V) yields 
an RMSD of 0.65 Å, indicating a high homology between each other (Figure 3-2 A). 
Four of the mshA mutants have single amino acid mutation (Table 3-2). These 
four amino acids (Arg273, Gly299, Gly356 and Glu361) are conserved in CgMshA (as 
Arg231, Gly263, Gly319 and Glu324) (Figure 3-2 A and B). Each of these amino acids 
plays an important role in either the substrate binding or the domain interaction (Figure 
3-2 B). The side-chain amines of Arg273 interact with the β-phosphate of UDP via 
hydrogen bonding. This arginine is also one of the major determinants of the orientation 
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of the inositol-phosphate as its side-chain lies against the face of inositol. Gly299 is not 
in the vicinity of the active site, but should be important for the protein stability as the 
next residue, Gly300, forms the only interdomain hydrogen bond with Gly61. Although 
not directly seen in the model, Gly356 was proposed to be involved in the binding of the 
N-acetyl-glucosamine moiety which shall be transferred from UDP to inositol(Matthew 
Vetting et al., 2008). In mc24936, the Glu361Ala mutation removes the side-chain 
carboxylate that forms hydrogen bonds with the 2′- and 3′-hydroxyls from the ribose 
moiety of UDP, which could result in the inactivation of MshA. 
The other mshA mutants had either nonsense or frameshift mutations (Figure 3-2 
C). In mc24931 and mc24934, the nonsense mutations caused the loss of active-site 
elements. In mc24937, the truncation of the protein was close to the C-terminus and the 
active site was unlikely to be affected. Herein the inactivation of MshA could be 
explained by the protein's characteristic folding. Based on the homology model of 
MshA, each monomer is composed of N-terminal and C-terminal domains. Towards the 
end of C-terminus, a large α-helix spanning Cys409 to Ile445 crosses back to the N-
terminal, which is likely to stabilize the overall folding of the protein. Therefore the 
mutations within this α-helix, such as in mc24937, would detrimentally affect the 
conformation of MshA leading to its inactivation. 
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Figure 3-2. Comparison of the MshA structures of M. tuberculosis and Corynebacterium 
glutamicum establishes a rationale for the inactivation of MshA in the mutants.(Catherine 
Vilchèze et al., 2008) 
(A) Ribbon representation of the superimposed M. tuberculosis MshA model (green) and 
CgMshA structure (blue) complexed with UDP/inositol-phosphate. Both UDP and inositol-
phosphate are shown as stick with transparent surface. Four amino acids, whose mutation led to 
M. tuberculosis MshA inactivation, are represented as CPK structures and labeled accordingly. 
(B) Active-site architecture of the superimposed MshA structures shown in (A). UDP and 
inositol-phosphate are shown as ball and stick. The four amino acid mutations R273, G299, 
G356 and E361, highlighted in (A), are shown as stick in white scheme, and the conserved 
residues in CgMshA are in white scheme, and the conserved residues in CgMshA are in blue 
scheme. Hydrogen bonds between the side-chain amines of Arg273 and the β-phosphate of UDP, 
as well as those between the side-chain carboxylate of Glu361 and the ribosyl hydroxyl groups 
of UDP are shown as black dotted lines. The residue numbers are for M. tuberculosis MshA. 
(C) Alignment of the M. tuberculosis and C. glutamicum mshA sequences. The mutations 
identified in the M. tuberculosis mshA mutants are indicated. The four amino acid changes are in 
bold. The stop codons or frameshift are pointed by arrows. The residues in the α-helix crossing 
from C-terminal to N-terminal domain are underlined. 
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Mycothiol promotes ETH activation by the ethA-encoded mono-oxygenase 
As the null mutants showed low (twofold the MIC) to no resistance to INH but 
showed a high level of resistance to ETH (≥ 6-fold the MIC), we therefore postulated 
that mycothiol could be involved in either ETH activation or ETH-NAD adduct 
formation in M. tuberculosis. ETH is activated by the NADPH-specific FAD-containing 
mono-oxygenase EthA(Alain Baulard et al., 2000; Andrea DeBarber et al., 2000; 
Tommaso Vannelli et al., 2002).” The activity can be evaluated by monitoring the 
oxidation of NADPH aerobically (Figure 3-3 A). We have found a higher activity of 
EthA in the presence of mycothiol (Figure 3-3 B), and observed “an increase in the 
reaction rate directly proportional to the increase in mycothiol concentration (Table 3-3), 
suggesting that mycothiol plays a role in the activation steps rather than in the formation 
of the ETH-NAD adduct. Furthermore, replacing mycothiol by a different thiol, such as 
reduced glutathione, had no effect on the oxidation rate of NADPH (data not shown). 
This suggests that the increase in EthA activity upon the addition of mycothiol is 
specific to mycothiol, and does not occur in the presence of another thiol. To test if 
mycothiol was also required for the formation of the ETH-NAD adduct, the rate of 
inhibition of InhA by ETH in the presence of NAD+, NADPH, EthA and mycothiol was 
also measured. No formation of the ETH-NAD adduct was observed in these conditions 
(data not shown), which suggests that mycothiol is not involved in the formation of the 
ETH-NAD adduct. Two other anti-TB drugs, isoxyl and thiacetazone, are also activated 
by EthA(Lynn Dover et al., 2007). We therefore tested if the mshA mutants (null and 
point mutants) were also resistant to isoxyl and thiacetazone and found that they were 
  78 
fully sensitive to both drugs (data not shown). This implies that mycothiol is solely 
involved in the activation of ETH. We could hypothesize that mycothiol either stabilizes 
the intermediates formed upon activation of ETH or forms a complex with the active 
form of ETH, which allows for the formation of the ETH-NAD adduct. More in-depth 
studies are necessary to fully understand which role mycothiol plays in the activation 
step. 
 
A 
 
B 
 
 
Figure 3-3. Mycothiol promotes ETH activation by the ethA-encoded mono-oxygenase. 
(A) EthA mediated NADPH oxidation aerobically(Bruce Palfey and Claudia McDonald, 2010). 
(B) Lineweaver–Burk plots for the NADPH oxidation catalyzed by EthA in the absence or 
presence of mycothiol. Without the additive, kcat = 0.0063 s-1 which was comparable with the 
previous report(Marco Fraaije et al., 2004). When 26 µM mycothiol was added in the reaction, 
the kcat was increased to 0.0115 s-1. 
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Table 3-3. The effect of mycothiol on EthA activity.(Catherine Vilchèze et al., 2008) 
[mycothiol] (µM) [NADPH]/s (µM /s) NADPH/EthA (mmol/s/mg protein) 
0 0.0071 1.24*10-4 
4.38 0.0074 1.29*10-4 
17.5 0.0094 1.64*10-4 
26.2 0.0111 1.94*10-4 
43.8 0.0127 2.23*10-4 
 
Experimental Procedure 
Cloning, expression, and purification 
The M. tuberculosis dfrA and katG genes were cloned as previously 
described(Argyrides Argyrou et al., 2006b). The plasmids of M. tuberculosis katG and 
dfrA were singly and doubly transformed into E. coli BL21(DE3) (EMD Bioscience, 
catalog no. 69387-3). The strain containing plasmids of katG and dfrA was cultured in 
LB-Miller medium containing 50 µg of kanamycin/ml and 50 µg of carbenicillin/ml at 
37°C until the optical density (OD) at 600 nm reached 0.5. Expression of both genes was 
carried out by induction for 20 h at 18°C by the addition of 1 mM IPTG. At the same 
time of induction, 100 µg of INH/ml was also added to the culture. The same protocol 
was used for the strain containing just the dfrA plasmid. Recombinant M. tuberculosis 
DhfR was purified according to a previously described method(John Belisle et al., 1997). 
The M. tuberculosis inhA and katG genes were cloned into pET30b and 
pDEST17 vectors, respectively, and then co-transformed into E. coli BL21(DE3). The 
strain containing both plasmids was cultured in LB medium containing 50 µg of 
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kanamycin/ml and 50 µg of carbenicillin/ml at 37°C until OD600 reached 0.5. Expression 
of both genes was carried out by induction for 20 h at 18°C by the addition of 1 mM 
IPTG. At the same time of induction, 100 µg of INH/ml was also added to the culture. 
The proteins of InhA and KatG were co-purified by Ni-column followed by octyl 
sepharose hydrophobic column. 
 
Enzymatic assays 
All assays were carried out on a Cary 100 Bio Spectrophotometer at 25°C. DhfR 
assays are performed by monitoring the oxidation of NADPH and reduction of 
dihydrofolate (DHF) at 340 nm. Reactions were initiated by adding DhfR (10 nM) to 
assay mixtures containing NADPH (10 µM), DHF (4.5 µM), and phosphate buffer (pH 
7.5, 50 mM). The KatG activity was assayed as previously described(Xiangbo Zhao et 
al., 2006). The InhA activity was assayed as previously described(Feng Wang et al., 
2007b). 
 
Mass spectroscopy analysis 
Purified DHFR was heated for 60 s at 100°C. After the heat treatment, denatured 
enzyme was separated by filtration, using a Centricon (cutoff, 3 kDa). The filtrate was 
used for mass analysis. The matrix-assisted laser desorption ionization (MALDI) mass 
spectrometry experiment was carried out on an ABI Voyager-DE STR. 
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Crystallization of InhA in complex with INH-NAD adduct and data collection 
Crystallization was accomplished by the hanging-drop vapor diffusion method. 
M. tuberculosis InhA in complex with INH-NAD was obtained in hanging droplets 
containing 2 µl of protein solution at 10 mg/ml and with 2 µl of buffer (12% 2-methyl-
2,4-pentanediol, 4% dimethyl sulfoxide, 0.1 M HEPES, and 0.025 M sodium citrate) at 
16°C in Linbro plates against 1 ml of the same buffer. To obtain a good occupancy of 
the INH-NAD adduct, 500 µL of InhA (10 mg/mL) co-expressed with KatG was 
denatured by heating to release INH-NAD. The denatured proteins were removed by 
centrifugation. The resulted INH-NAD solution was incubated with 50 µL InhA (10 
mg/mL) on ice for 30 min, and the mixture was concentrated to a volume of 50 µL for 
purpose of crystallization. Diamond shaped protein crystals formed about 4 days later. 
Diffraction data of single InhA crystal was collected to at the wavelength of 
1.542 Å using Rigaku R-AXIS IV++ at home source. All the data were processed and 
reduced using HKL2000(Zbyszek Otwinowski and Wladek Minor, 1997). It is in the 
space group P6222, with one molecule in each asymmetric unit (Table 3-1). 
 
Structure determination and model refinement 
The structure of InhA was solved by molecular replacement using Molrep(Alexei 
Vagin and Alexei Teplyakov, 1997) in CCP4. InhA (PDB code 1ZID) with all 
nonprotein molecules removed, was used as the search model. A single solution for the 
molecular replacement was obtained. Isonicotinoyl-NAD (INH-NAD) was manually 
built in the active site of the model by examining the Fo - Fc map in Coot(Paul Emsleya 
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and Kevin Cowtan, 2004). The final model containing residues 2–269 as well as 16 
water molecules was obtained after further cycles of model building and PHENIX 
refinement(Afonine et al., 2005) yielding R factors of 20.8% and 25.6%. The full 
crystallization statistics are given in Table 3-1. 
 
Isolation of INH- and ETH-resistant spontaneous mutants 
Mycobacterium tuberculosis H37Rv mutants were isolated from non-
mutagenized cultures grown in the media described above. The cultures were incubated 
by shaking at 37°C to late log phase. Ten-fold serial dilutions were then plated on agar 
plates (media described above) containing INH (0.2 µg ml−1) and ETH (5 or 10 µg ml−1). 
The plates were then incubated at 37°C for 6 weeks. 
 
MIC determination 
The strains were grown to an OD600≈ 1.0. Ten-fold serial dilutions were plated on 
plates containing INH (0, 0.1, 0.2, 0.25, 0.3, 0.4, 0.5, 0.6, 0.8, 1 µg ml−1) or ETH (0, 2.5, 
5, 10, 15, 20 µg ml−1). The MIC was determined as the concentration of drug that 
reduced the number of colony-forming units (cfu) ml−1 by 99%. MICs were also 
determined using the MTT assay(Martin et al., 2005). 
 
EthA enzymatic activity assay 
The his-tagged EthA was produced, as previously described(Lynn Dover et al., 
2007). The activity of EthA was determined by monitoring the absorbance decrease of 
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NADPH at 340 nm (ε340 nm = 6.22 mM−1 cm−1). All the reactions were catalysed by ∼1 µM 
EthA and performed in 50 mM Tris/HCl, pH 7.5. Double reciprocal plots were used to 
determine the kcat of the oxidation of NADPH. For measuring the effect of mycothiol, 
reaction mixtures contained 200 µM NADPH and varying mycothiol concentrations. 
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CHAPTER IV 
STRUCTURES OF MYCOBACTERIUM TUBERCULOSIS FADD10 PROTEIN 
REVEAL A NEW TYPE OF ADENYLATE-FORMING ENZYME* 
 
Summary 
Mycobacterium tuberculosis has a group of 34 FadD proteins that belong to the 
adenylate-forming superfamily. They are classified as either fatty acyl-AMP ligases 
(FAALs) or fatty acyl-CoA ligases (FACLs) based on sequence analysis. FadD10, 
involved in the synthesis of a virulence-related lipopeptide, was mis-annotated as a 
FACL, however, it is in fact a FAAL that transfers fatty acids to an acyl carrier protein 
(Rv0100). In this study, we have determined the structures of FadD10 in both the apo 
and the complexed form with dodecanoyl-AMP, where we see for the first time an 
adenylate-forming enzyme that does not adopt a closed conformation for catalysis. 
Indeed, this novel conformation of FadD10, facilitated by its unique inter-domain and 
intermolecular interactions, is critical for the enzyme to carry out the acyl transfer onto 
Rv0100 rather than Coenzyme A. This contradicts the existing model of FAALs that rely 
on an insertion motif for the acyl transferase specificity, and thus makes FadD10 a new 
type of FAAL. We have also characterized the fatty acid preference of FadD10 through 
                                                
* This work has been published in and is reprinted with permission from: 
Zhen Liu, Thomas Ioerger, Feng Wang, and James Sacchettini. “Structures of 
Mycobacterium tuberculosis FadD10 protein reveal a new type of adenylate-forming 
enzyme” The Journal of Biological Chemistry 2013, 288 (25): 18473-83 Copyright 2013 
(American Society for Biochemistry and Molecular Biology). 
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biological and structural analyses, and the data indicate long chain saturated fatty acids 
as the biological substrates of the enzyme. 
 
Introduction 
Adenylate-forming enzymes are found in a variety of important biological 
processes in both eukaryotes and prokaryotes(Stefan Schmelz and James Naismith, 
2009). They show wide diversity in their catalytic activities and biological functions. 
The adenylate-forming superfamily of enzymes is composed of luciferases, amino acid 
adenylation domains of non-ribosomal peptide synthetases (NRPSs), acyl-Coenzyme A 
(acyl-CoA) synthetases, and acyl-acyl carrier protein (acyl-ACP) synthetases. These 
enzymes first use ATP to adenylate the carboxylate group of the cognate substrate, 
which is then followed by the transfer of the acyl moieties to the corresponding 
acceptors, for example, luciferyl to oxygen, amino acyl to peptidyl carrier protein (PCP) 
domains, and fatty acyl to CoA or ACPs. The fatty acyl-CoA synthetases (EC 6.2.1.3) 
and fatty acyl-ACP synthetases (EC 6.2.1.20) have also been referred to as fatty acyl-
CoA ligases (FACLs) and fatty acyl-AMP ligases (FAALs), respectively(Benjamin 
Duckworth et al., 2012; Omita Trivedi et al., 2004; Pooja Arora et al., 2009; Zhening 
Zhang et al., 2011). Both enzymes have acyl-AMP ligase activity. However, FACLs 
transfer fatty acyl chains to Coenzyme A, while FAALs transfer fatty acyl chains to 
ACPs. 
Within the genome of Mycobacterium tuberculosis (M. tuberculosis), there are 
34 fadD genes that have been annotated to be members of the adenylate-forming 
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superfamily(Jean-Christophe Camus et al., 2002). Although the precise functions of 
most are unclear, several have been shown to be involved in the synthesis of bioactive 
lipids that are essential for bacterial survival or virulence(Israël Casabon et al., 2012; 
Kathleen Y. Dunphy et al., 2010; Laura Rindi et al., 2004; Roxane Siméone et al., 2010), 
and thus represent potential targets for drug discovery. Multi-sequence alignment of the 
34 M. tuberculosis FadDs revealed two subclasses: 12 FAALs and 22 FACLs(Omita 
Trivedi et al., 2004). The 12 FAALs share a much higher sequence homology (70%-80% 
identity) than the FACLs (20%-30% identity). Interestingly, 10 of the 12 M. tuberculosis 
FAAL-encoding genes are located in close proximity to multienzyme polyketide 
synthases. Biochemical studies have shown that three of the FAALs (FAAL26, 
FAAL30, and FAAL32) transfer long chain fatty acyl moieties to the polyketide 
synthases: PpsA, PKS6, and PKS13, respectively(Mathieu Léger et al., 2009; Omita 
Trivedi et al., 2004; Sabine Gavalda et al., 2009). Therefore, it has been suggested that 
FAAL enzymes activate fatty acids as adenylate derivatives and sequentially transfer 
acyl moieties to cognate modular enzymes, particularly their ACP domains, to be further 
processed into complex lipids(Omita Trivedi et al., 2004; Pooja Arora et al., 2009). 
Recent structural and biochemical studies of M. tuberculosis FAAL28(Pooja Arora et 
al., 2009) and FAALs from E. coli, and L. pneumophila(Zhening Zhang et al., 2011) 
have provided a molecular basis for their catalytic mechanism. These studies have 
identified a signature sequence motif, consisting of an insertion of about 20 amino acids, 
that defines the function of this newly recognized subclass of the adenylate-forming 
  87 
superfamily and distinguishes them from FACLs(Aneesh Goyal et al., 2011; Pooja Arora 
et al., 2009). 
FadD10 (Rv0099) is present on an operon consisting of Rv0096 – Rv0101. The 
operon has been the subject of many studies(Arush Chhabraa et al., 2012; Feng Wang et 
al., 2007a; Grant Hotter et al., 2005) because it is involved in making a virulence-
essential lipopeptide using an NRPS (Rv0101, nrp). M. smegmatis has a similar NPRS, 
called mps, which synthesizes a glycopeptidolipid(Helen Billman-Jacobe et al., 1999). 
We have shown that Rv0098(Feng Wang et al., 2007a) is a fatty acyl-CoA thioesterase. 
While the identity of the lipopeptide produced by M. tuberculosis Rv0096-Rv0101 
operon is not known, its biological significance was indicated in several studies. For 
example, Rv0096 was demonstrated to be required for M. tuberculosis survival in mouse 
macrophages(Jyothi Rengarajan et al., 2005), and Rv0098-Rv0101 were predicted, using 
transposon site hybridization, to be required for M. tuberculosis survival in a mouse 
model of infection(Christopher Sassetti and Eric Rubin, 2003). It has been suggested that 
the products of the operon repressed the SigM factor that further regulates a series of 
metabolic pathways and modulates the host-bacteria interactions(Sahadevan Raman et 
al., 2006). In spite of the biological significance of the lipopeptide produced by the 
Rv0096-Rv0101 operon, neither the isolation nor the identity of this lipopeptide have 
been reported; therefore, an alternative approach to define its chemical structure is to 
characterize the function and mechanism of the individual proteins involved in its 
synthesis. 
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Rv0098-Rv0101 are essential for M. tuberculosis survival in the mouse model of 
infection(Christopher Sassetti and Eric Rubin, 2003). Hence they likely to have direct 
enzymatic roles in the synthesis of the virulence-related lipopeptide product of the 
operon. As mentioned above, our biochemical and structural characterization of Rv0098 
has shown that it encodes a thioesterase capable of hydrolyzing a long chain fatty acyl-
CoA to release a fatty acid and Coenzyme A(Feng Wang et al., 2007a). Rv0100 is 
clearly an ACP according to sequence analysis, and it shares 24.4% sequence identity to 
the primary M. tuberculosis ACP  (Rv0033) involved in type II fatty acid biosynthesis. 
Rv0101 is a two-module NRPS, with the first module of an undefined amino acid 
specificity and the second module to incorporate phenylalanine(Marc Röttig et al., 
2011). M. tuberculosis FadD10 (Rv0099) was designated as an FACL based on 
sequence analysis(Omita Trivedi et al., 2004). However, the presence of a thioesterase 
(Rv0098) immediately upstream suggests that fadD10 is unlikely to function as an acyl-
CoA sythetase because this would put two enzymes with opposing functions next to each 
other in the operon. Indeed, the fact that fadD10 is located in close proximity with a 
multi-function enzyme (Rv0101) is analogous to the M. tuberculosis  FAALs. These 
findings suggest that M. tuberculosis FadD10 activates and transfers the fatty acyl chain 
to the cognate ACP - Rv0100. Chhabraa et al. recently showed that FadD10 does not 
acylate CoA, but is able to transfer a radioactively labeled dodecanoyl moiety to Rv0100 
in vitro(Arush Chhabraa et al., 2012). This suggests that FadD10 has FAAL activity 
even though it has a primary sequence more similar to FACLs. FadD10 has much lower 
sequence similarity to the members of the M. tuberculosis FAALs cluster and moreover 
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lacks the signature motif critical for FAAL activity (Figure 4-1); hence, it is intriguing to 
delineate the molecular basis underlying this discrepancy. 
 
 
Figure 4-1. Mutisequence-alignment of M. tuberculosis FadDs reveals a signature insertion 
(boxed) for FAALs cluster. 
 
In this study, we have solved the structures of both apo and dodencanoyl-AMP 
bound M. tuberculosis FadD10, leading to the characterization of a novel ligand bound 
conformation for the adenylate-forming superfamily. Instead of undergoing 
conformational rearrangement between the N- and C-terminal domains, as observed in 
all the other reported adenylate-forming homologues(Andrew Gulick, 2009), FadD10 
retains a single open conformational state for both the apo- and ligand-bound forms. We 
find that FadD10's FAAL activity can be explained by its unique inter-domain and 
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intermolecular interactions, a mechanism distinct from that known for the other FAALs. 
Our modeling studies identify the binding site of the ACP (Rv0100) onto FadD10 in the 
acyl transfer reaction. Also, our studies provide a structural basis for the fatty acid 
preference of M. tuberculosis FadD10, which may eventually aid in elucidating the 
chemical structure of the virulence-related lipopeptide produced by the Rv0096-Rv0101 
operon. 
 
Results and Discussion 
Crystal structures of M. tuberculosis FadD10 subunit 
In order to understand the molecular basis of the FAAL activity of FadD10 
arising from a primary sequence more similar to FACLs, we have determined the 
structures of FadD10 in both apo and complexed forms. The full-length apo M. 
tuberculosis FadD10 crystallized in space group P21 and its structure was solved using 
Selenium-Single-wavelength Anomalous Dispersion. The asymmetric unit contains a 
dimer (Figure 4-2 A), consistent with the gel filtration analysis. The two subunits are 
very similar with an RMSD of 0.68 Å for 491 α carbons after superimposition (Figure 4-
2 C). For the chains designated as A and B, a total of 508 and 502 out of 540 residues, 
respectively, were visible and built into the electron density. Residues S178, T181, 
E183, and K185 of chain A and residues E426, R451, S474, E476, and L477 of chain B 
were built as alanine due to ambiguous side chain electron density. The structure was 
refined to 2.2 Å resolution with a final R-factor of 22.7% and a R-free of 27.3%. 
Statistics of the refined structures are listed in Table 1. 
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FadD10 complexed with the half-reaction product dodecanoyl-AMP crystallized 
in space group P3121. Its structure was solved by molecular replacement using chain A 
of our refined apo structure as the search model. Dodecanoyl-AMP was built into a clear 
electron density (Fo – Fc map) located at the active site (Figure 4-2 B). In this crystal, 
M. tuberculosis FadD10 packed with one molecule per asymmetric unit, and the two 
subunits of the dimer are related to each other by a crystallographic 2-fold symmetry. 
The structure, with 508 residues built into the electron density, was refined to 2.8 Å 
resolution with a R- factor of 22.6% and a R-free of 27.9%. Superposition of the 
complexed M. tuberculosis FadD10 subunit with the chain A and chain B from the apo 
crystal yields an RMSD of 0.596 Å and 0.637 Å, respectively, for the α-carbons (Figure 
4-2 C). 
Each subunit of M. tuberculosis FadD10 is composed of two domains (Figure 4-2 
D). The N−terminal domain consists of 420 amino acids (residue 1-420), forming a 
central α/β structure surrounded by a distorted β−sheet on one side and three β−strands 
with intervening α−helices on the other side. The loop containing the residues 
421KGRSS425 extends from the β−strand B15 and continues into the C-terminal domain, 
consisting of 115 amino acids (residue 426-540). This domain is composed of three β-
strands surrounded by two α-helices and a pair of short anti-parallel β-strands at the 
beginning of the domain. 
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Figure 4-2. The structures of apo- and complexed FadD10 with dodecanoyl-AMP. 
(A) Ribbon representation of the dimeric FadD10. The N-terminal domains of the two subunits, 
designated as A and B, are colored yellow and green, while the corresponding C-terminal 
domains are colored orange and cyan, respectively. 
(B) Fo – Fc map is calculated when dodecanoyl-AMP and magnesium ion are omitted from the 
model, and is contoured at 2 sigma level. 
(C) FadD10 (grey) in complex with dodecanoyl-AMP (pink) is superimposed with the two 
subunits (colored as in Figure 2A) from the apo structure. 
(D) Cylinder representation of FadD10 that demonstrates the 2-domain organization and the 
secondary structure elements of each subunit. The inter-domain loop is colored in black. 
(E)	  The inter-domain hydrogen bonds shown as dotted lines. The residues involved in the 
interactions are shown in stick. The identity of the helices involved in forming the hydrogen 
bonds is marked in color. 
 
Analysis of the complexed FadD10 subunit structure using VAST (Vector 
Alignment Search Tool)(Jean-Francois Gibrata et al., 1996) revealed that the highest 
structural similarity was with adenylate-forming enzymes, namely Alcaligenes sp. 4-
chlorobenzoate-CoA synthetase (CBL), the M. tuberculosis very-long-chain fatty acyl-
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CoA synthetase FACL13, and the N. lolii NRPS activation domain SidNA3. 
Superposition of the full-length M. tuberculosis FadD10 with these structures yielded 
fairly poor alignments. For instance, superposition between M. tuberculosis FadD10 and 
FACL13 (PDB ID: 3R44) showed an alignment with only part (301 out of 420 α-
carbons) of the N-terminal domain (RMSD 2.61 Å).  When the N-terminal domains were 
aligned, the C-terminal domains were found to be in a completely different orientation, 
even though the secondary structural elements of their C-terminal domains were quite 
similar. Indeed, dividing FadD10 into N-terminal and C-terminal domains allowed 80% 
of its N-terminal structure and 70% of the C-terminal structure to align with FACL13, 
yielding RMSD of 2.80 Å for 345 N-terminal domain α-carbons and 4.24 Å for 101 C-
terminal domain α-carbons. A similar result was observed when M. tuberculosis FadD10 
was compared with the other adenylate-forming homologues identified by VAST, i. e. 
structural superposition could only be obtained when the N-terminal and C-terminal 
domains were overlaid independently.  While all of the adenylate-forming enzymes 
complexed with adenylate (including analogs) share a similar inter-domain orientation, 
M. tuberculosis FadD10 adopts a distinctive inter-domain conformation (Figure 4-3 A). 
As expected, similar alignments were obtained with the apo structure of FadD10. 
The adenylate-forming superfamily of proteins that have been structurally 
characterized revealed remarkable conformational flexibility between the N- and C-
terminal domains(Andrew Gulick et al., 2004; Charlotta S. Andersson et al., 2012; Elena 
Conti et al., 1996; Grazyna Kochan et al., 2009; Jurgen May et al., 2002; Manish Shah et 
al., 2009; Yuko Hisanaga et al., 2004). The inter-domain orientations of these proteins 
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vary noticeably among the apo structures as well as between the apo and the respective 
ligand bound structures of the individual proteins. Such variations are not correlated to 
the functions of different subclasses. They likely arise because the two domains form no 
significant protein-protein inter-domain contacts and are connected by only a flexible 
loop. This feature allows the two domains to rearrange upon substrates binding in order 
to desolvate the active site, a process that has been referred to as the “domain 
alternation” mechanism for the adenylete-forming superfamily(Andrew Gulick, 2009). 
This mode of ligand binding is exemplified by the Thermus thermophilus long chain 
fatty acyl-CoA synthetase (LC-FACS)(Yuko Hisanaga et al., 2004). When this protein 
binds AMPPNP or myristyl-AMP, its C-terminal domain rotates almost 180° relative to 
the inter-domain linkage loop (432DRLK435) and moves towards the N-terminal domain 
forming a lid over the active site. A similar rearrangement, with varying extents of 
rotation, has also been observed for P. pyralis luciferase(Elena Conti et al., 1996), the 
aryl acid adenylation domain of bacillibactin synthetase (DhbE)(Jurgen May et al., 
2002), Alcaligenes sp. CBL(Andrew Gulick et al., 2004), and H. sapiens medium chain 
acyl-CoA synthetase(Grazyna Kochan et al., 2009), for which both apo and ligand-
bound structures are available. Thus, the closure of the C-terminal domain toward the N-
terminal domain is believed to be a common substrate binding event for the adenylate-
forming superfamily. In this respect, M. tuberculosis FadD10 is clearly unique in 
comparison to other homologous adenylate-forming proteins, as it maintains an “open” 
conformation for the apo structure, as well as for FadD10 complexed to the half-reaction 
product dodecanoyl-AMP.  
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A novel ligand-bound conformation of M. tuberculosis FadD10 
 
 
Figure 4-3. The unique inter-domain interaction of FadD10 contributes to the conformational 
maintenance. 
(A) FadD10 (yellow) complexed with dodecanoyl-AMP (ball and stick) is aligned with human 
medium chain acyl-CoA synthetase (gray, PDB ID: 3DAY) at their N-terminal domains. The 
latter is shown only the C-terminal domain, and the N-terminal domain of FadD10 is shown in 
carbon trace for clarity. 
(B) The variation of the secondary structure equivalent to FadD10 helix A11 (i), among 
adenylate-forming enzymes, is exemplified by ii. M. tuberculosis FACL13 (PDB ID: 3R44), iii. 
M. tuberculosis FAAL28 (PDB ID: 3E53), and iv. B. brevis PheA (PDB ID: 1AMU). E340 in 
FadD10 is shown as ball and stick. A11 and its equivalents are colored red. 
 
The apo and complexed structures of M. tuberculosis FadD10 have provided 
several insights into the structural determinants for its unique “open” ligand bound 
conformation. The first factor that contributes to the maintenance of the open 
conformation in the M. tuberculosis FadD10 structures is the inter-domain interactions 
between the α-helix A15 from the C-terminal domain and the three-helix (A9, A10, 
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A11) cluster from the N-terminal domain (Figure 4-2 E).  Specifically, the side-chain 
oxygen of Ser524 forms hydrogen bonds with both the side-chain oxygen of Glu340 (2.5 
Å) and the backbone nitrogen of Ala301 (3.3 Å). More inter-domain hydrogen bonds are 
formed by the backbone nitrogens of Ala523 (3.1 Å) and Ser524 (3.3 Å) with the side-
chain carboxylate of Glu340, as well as between the side-chain amine of Lys279 and the 
side-chain oxygen atoms of Asp511 (3.1 Å and 3.3 Å). These interactions are maintained 
in both the apo M. tuberculosis FadD10 structure and the complexed structure with 
dodecanoyl-AMP, which greatly limits the inter-domain movement of the protein. A 
similar inter-domain contact has not been observed in the other adenylate-forming 
proteins. The reason is likely due to the absence of the structural elements found in M. 
tuberculosis FadD10 accounting for this interaction. While A9, A10, and A15 are 
structurally conserved, the structural equivalent to helix A11 of FadD10 (Figure 4-3 B i) 
notably varies among adenylate-forming proteins. A short helix equivalent to A11 is 
found present in only four members, including the adenylation domains DhbE(Jurgen 
May et al., 2002) and DltA(Huma Yonus et al., 2008), as well as the acyl-CoA 
synthetases LC-FACS(Yuko Hisanaga et al., 2004) and M. tuberculosis 
FACL13(Charlotta S. Andersson et al., 2012). However, the glutamate residue (E340) 
essential to forming inter-domain hydrogen bonds in M. tuberculosis FadD10 is replaced 
by non-polar residues in these four homologous proteins (Figure 4-3 B ii). A significant 
structural alteration of A11 is observed in FAALs, including the N-terminal domain of 
M. tuberculosis FAAL28(Pooja Arora et al., 2009), the full-length E. coli, and L. 
pneumophila FAALs(Zhening Zhang et al., 2011), where the helix A11  is replaced by a 
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β-strand followed by an α-helix or a loop (Figure 4-3 B iii). This is the location where 
the ~20-amino-acid insertion motif occurs in FAALs, which has been implicated in 
determining FAAL activity. In all of the other structures that have been determined for 
the adenylate-forming superfamily, the region equivalent to the helix A11 is disordered 
(Figure 4-3 B iv). 
The second factor contributing to the rigidity of M. tuberculosis FadD10 open 
conformation arises from the quaternary organization of the dimer. According to the 
current understanding of adenylate-forming proteins, most of them, including 
FAALs(Zhening Zhang et al., 2011), are functional as monomers. The only subclass that 
can form dimers are the acyl-CoA synthetases, and for these proteins the dimerization 
interface is always limited to the N-terminal domains. This observation is consistent with 
the acyl-CoA synthetic mechanism, which requires the C-terminal domain to move 
freely relative to the N-terminal domain in order to bind ATP and then Coenzyme A in 
the step-wise reactions. M. tuberculosis FadD10 is also shown to be a dimer in solution 
based on both gel filtration analysis (data not shown), and PISA (Protein Interfaces, 
Surfaces and Assemblies) calculation(Evgeny Krissinel and Kim Henrick, 2007). In both 
the apo structure of M. tuberculosis FadD10 and its complexed structure with 
dodecanoyl-AMP, the two subunits of the dimer form an extensive network of 
intermolecular interactions, including 8 hydrogen bonds and many van der Waals 
interactions. All of the hydrogen bonds and most of the van der Waals interactions are 
between residues from the C-terminal domain of one subunit and residues from the N-
terminal domain of the other subunit. This confers a contact area of about 1600 Å2 per 
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22000 Å2 for each subunit. FadD10 is the first adenylate forming enzyme other than 
acyl-CoA synthetases, to be identified as a dimer. More importantly, the two subunits of 
the dimer interact in a manner which was previously unseen in the other homologs, and 
we propose this dimerization mode has played a role in maintaining the “open” 
conformation of M. tuberculosis FadD10 upon binding dodecanoyl-AMP. 
  
The conformation of M. tuberculosis FadD10 prevents Coenzyme A binding 
The adenylate-forming proteins, as a superfamily, share 10 conserved sequence 
motifs(Mohamed Marahiel et al., 1997), a similar structural scaffold(Andrew Gulick, 
2009), and a common half reaction -the adenylation of the carboxylate group of a 
substrate. Moreover, structural characterization of the superfamily revealed that a 
phosphopantetheine binding cavity is structurally conserved in the N-terminal domain. 
This is consistent with the notion of an evolutionary relationship within the adenylate-
forming superfamily, and strongly argues that the ubiquitous acyl-CoA synthetases are 
likely to be ancestral(Aneesh Goyal et al., 2011; Hugo Fraga et al., 2004; Uwe Linnea et 
al., 2007). Functional conservation of acyl-CoA synthesis activity has also been reported 
in other sub-classes of the adenylate-forming superfamily. For example, firefly 
luciferase(Hugo Fraga et al., 2004) as well as five different adenylation domains of 
NRPSs(Uwe Linnea et al., 2007) were shown to synthesize luciferyl-CoA and 
aminoacyl-CoAs, respectively, when their genuine acyl acceptors were absent and 
Coenzyme A was added as substrate. In contrast, M. tuberculosis FAALs (acyl-ACP 
synthetases) that have been studied, to date, which have also been proposed to be 
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descendants of acyl-CoA synthetases, lack acyl-CoA synthesis activity(Aneesh Goyal et 
al., 2011; Pooja Arora et al., 2009), even though they retain the binding elements of 
phosphopantetheine. This was demonstrated as well for FadD10. 
Structural comparison and analyses of relative domain orientation of FAALs and 
FadD10 with acyl-CoA synthetases provides a plausible explanation to their inability to 
turnover acyl-CoA. The structures of three acyl-CoA synthetases, Alcaligenes sp. CBL, 
human medium chain fatty acyl-CoA synthetase, and E. coli acetyl-CoA synthetase have 
all been reported in complex with Coenzyme A or derivatives(Andrew Gulick et al., 
2003; Andrew Gulick et al., 2004; Grazyna Kochan et al., 2009). When these proteins 
bind to Coenzyme A, their C-terminal domains all rotate about 140° relative to the 
position in the adenylate bound form.  Also, for all of these proteins, the C-terminal 
domain is explicitly engaged in the binding of Coenzyme A through hydrophobic 
interactions with its nucleotide moiety. This domain reorganization is believed to be 
requisite for Coenzyme A binding by the adenylate-forming enzymes, and hence for the 
formation of acyl-CoA. 
 Sequence analysis of M. tuberculosis FadD proteins reveals an N-terminal 
domain insertion of 10 to 24 amino acids only present in the FAAL cluster (Figure 4-1). 
Using the sequence insertion as an indicator, a number of putative FAALs can be 
identified in various organisms. Structural studies of E. coli FAAL, L. pneumophila 
FAAL(Zhening Zhang et al., 2011), and the N-terminal domain of M. tuberculosis 
FAAL28(Pooja Arora et al., 2009) indicate that the inserted sequence flanks the 
interface of the two domains. In M. tuberculosis FadD28 and E. coli FAAL, the insertion 
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folds into a β-strand followed by a short α-helix and a short extension of β-strand; in L. 
pneumophila FAAL, the insertion folds into a β-strand and then a loop. The structural 
insertion does not appear to interfere with the closure of the C-terminal domain to form 
the adenylate bound conformation(Zhening Zhang et al., 2011). However, it prevents the 
FAALs from undergoing the large-scale inter-domain rotation associated with 
Coenzyme A binding. The functional role of the insertion was further established, by 
showing that its deletion and addition manipulated the gain and loss of acyl-CoA 
synthesis activity in M. tuberculosis FAALs and FACLs, respectively(Aneesh Goyal et 
al., 2011; Pooja Arora et al., 2009). 
M. tuberculosis FadD10 does not have the FAALs insertion; therefore, the lack 
of acyl CoA synthesis activity for M. tuberculosis FadD10 must be based on a different 
mechanism. We propose that it is the unique inter-domain and intermolecular 
interactions of FadD10, as described above, that prevent the required inter-domain 
rearrangement for Coenzyme A binding. The introduction of an acyl moiety into a 
natural product made by. a PKS or NRPS is a well-recognized function of the acyl-CoA 
synthetases. While the acyl-CoA synthetases have been extensively studied, the CoA 
independent acyl transfer function has only been recently discovered and the 
understanding of its mechanism is limited to FAALs(Debasisa Mohanty et al., 2011). 
Functionally analogous to FAALs, M. tuberculosis FadD10 has revealed a distinct 
strategy to prevent acyl-CoA synthesis. It contradicts the existing model for the catalysis 
of FAALs dependent on an insertion motif, therefore establishes M. tuberculosis FadD10 
as a new type of FAAL. 
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Modeling studies of the interactions between M. tuberculosis FadD10 and Rv0100 
We have identified the likely binding interface for ACP (Rv0100) on FadD10. 
Because the transfer of a fatty acyl chain to the ACP by FadD10 is analogous to the 
transfer of amino acyl groups to peptidyl carrier proteins by NRPS adenylation domains, 
we have compared FadD10 with the structure of P. aeruginosa PA1221, which is a 
didomain construct containing an adenylation domain and a peptidyl carrier 
protein(Carter Mitchell et al., 2012). When the N-terminal domains of FadD10 and 
PA1221 adenylation domain (21% identity) are superimposed, their C-terminal domains 
are in different orientations as expected.  Interestingly, the peptidyl carrier protein of the 
didomain structure is positioned in an orientation poised for the FadD10 substrate to 
bind. Specifically, the side chain of the active site serine residue of the peptidyl carrier 
protein is directed toward and is approximately the correct distance to the 
phosphopantetheine binding cavity of FadD10 (Figure 4-4 A). When the interaction 
between FadD10 and the PA1221 peptidyl carrier protein is examined over the surface 
of the FadD10 dimer, we observe a relatively good fit of the carrier protein onto the 
intermolecular space of the dimer. Because ACPs are highly functionally and 
structurally homologous to the peptidyl carrier proteins, we have generated a homology 
model of Rv0100 based on the structure of PA1221 peptidyl carrier protein (19% 
identity)(Christophe Lambert et al., 2002). When the ACP model is overlaid on top of 
the superposition of FadD10 and PA1221, the interaction of ACP to FadD10 is similar to 
that of the PA1221 peptidyl carrier protein to FadD10 (Figure 4-4B), which suggests that 
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the open conformation of FadD10 has room for the ACP (Rv0100) to bind for acyl 
transfer. 
 
 
Figure 4-4. Modeling studies of the interactions between M. tubercuosis FadD10 and Rv0100. 
(A) Ribbon representation of the superposition of FadD10 subunit A with the didomain structure 
of PA1221 (PDB ID: 4DG9). The N-terminal and C-terminal domains of FadD10 are colored in 
yellow and orange, respectively. The N-terminal domain of the PA1221 adenylation domain is 
colored in white and its C-terminal domain is hidden for clarity. The PA1221 peptidyl carrier 
protein is colored in blue and its active site residue Ser533 is shown in stick. 
Phosphopantetheine, shown in green stick, is modeled based on comparison with human medium 
chain fatty acyl synthetase in complex with butyl-CoA (PDB ID: 3EQ6). 
(B) Surface representation of the interaction between the ACP (Rv0100) and FadD10 dimer. The 
subunit A of FadD10 dimer and PA1221 peptidyl carrier protein are colored as in panel A. The 
N-terminal and C-terminal domains of the FadD10 subunit B are colored in green and cyan, 
respectively. The Rv0100 model is shown as pink ribbon. 
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Substrate binding site of M. tuberculosis FadD10 
Several structures of adenylate-forming proteins in complex with adenylated 
derivatives (including three proteins bound to different long chain acyl-AMPs(Yuko 
Hisanaga et al., 2004; Zhening Zhang et al., 2011)) have been reported, wherein multiple 
residues from both the N-terminal and C-terminal domains are involved in the binding of 
adenylate moiety. However, the interactions between the amino acids of the C-terminal 
domain to the adenylate moiety are missing in M. tuberculosis FadD10, due to its open 
conformation. Conserved between FadD10 and the other homologous structures are 
primarily the interactions between the residues from the N-terminal domain of the 
enzyme and the adenylate group. The adenosine moiety, which is coordinated by a 
network of both hydrophobic interactions and hydrogen bonding (Figure 4-5 A), sits at 
the entrance to the catalytic cavity. The planar adenine is sandwiched by the 
hydrophobic side-chains of Tyr317 and Val344 on one side, and the backbone atoms of 
294GGSR297 on the other side. The exocyclic nitrogen forms hydrogen bonds with the 
side-chain oxygen of Gln315 (3.2 Å) and the backbone oxygen of Val316 (3.2 Å). The 
major binding determinants of ribose are Gly295 and Asp408. Specifically, the backbone 
oxygen of the former forms hydrogen bond (3.3 Å) with the ribose ring oxygen, and a 
side chain oxygen of the latter interacts with the 3’ (3.2 Å) ribosyl hydroxyl via 
hydrogen bond. The α-phosphate of AMP interacts with Ser320 by forming hydrogen 
bonds between the O2 of the phosphate and the backbone nitrogen (3.3 Å) of this 
residue. 
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The dodecanoyl aliphatic chain is buried inside a preformed narrow closed-end 
tunnel by β-strands B9, B10, B11, and α-helix A7 (Figure 4-5 B). In the apo structure of 
FadD10, this fatty acyl binding cavity is vacant. The tunnel that contains the aliphatic 
chain is lined primarily by the backbone atoms of B9, B10, and B11 (i.e. 264TCLV267, 
291VGYGG295, and 317YG318), while only three hydrophobic side chains, Val316, Ile226, 
and Trp231, are within van der Waal’s distance to the aliphatic chain. Approximately 11 
Å from the portal of the fatty acyl binding cavity, which is near the C12 of the 
dodecanoyl chain, the tunnel splits into two directions. In one direction, it extends along 
strand B9 to Leu290, whose dimethyl carbons are 5.5 Å from C12 of the dodecanoyl 
chain. In the other direction, it bends into a highly hydrophobic groove made by the side-
chains of Leu201, Val209, Trp211, Trp230, and Tyr348. At the distal end, it is 
terminated by the side chains of Val197 and Pro198. The bottom of this groove is about 
9.4 Å from C12 of the dodecanoyl chain, raising the possibility that the enzyme could 
accommodate a longer fatty acid substrate. We compared the fatty acid binding tunnels 
of the very long chain fatty acyl-CoA synthetase M. tuberculosis FACL13 (active on 
fatty acid with up to 26 carbons)(Charlotta S. Andersson et al., 2012), FadD10, and the 
human medium chain fatty acyl-CoA synthetase (active on fatty acid with up to 10 
carbons)(Grazyna Kochan et al., 2009). The linear distance between the distal end and 
the portal of their fatty acyl binding tunnels are approximately 17 Å, 14 Å, and 10 Å, 
respectively, which indicates that the biological substrate of FadD10 is probably a long 
chain fatty acid. Based on the geometric modeling and taking into account of the contact 
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distance associated with atomic van der Waals radii, the fatty acid binding tunnel in 
FadD10 could accommodate at most 16 carbons (i. e. hexadecanoic acid).   
To further determine the fatty acid specificity of FadD10, we incubated M. 
tuberculosis FadD10 and the holo-ACP (Rv0100), with fatty acids of varying chain 
length and degree of saturation, and then analyzed the results for the acylation of ACP 
(Rv0100) using ESI-QTOF mass spectrometry. We observed acylated ACP even when 
hexadecanoic acid was used as a substrate (Figure 4-5 C). This is consistent with the 
modeling study that shows a hexadecyl chain can be accommodated in the fatty acid 
binding tunnel of FadD10, and Chhabraa et al.’s study(Arush Chhabraa et al., 2012) 
showing that FadD10 could utilize fatty acids with up to 16 carbons in the adenylation 
reaction. The lower product yield for hexadecanoic acid could reflect differences in 
solubility or affinity. We have also observed a higher activity of FadD10 with 
hexadecanoic acid than 2-trans-hexadencenoic acid, which suggests that FadD10 prefers 
saturated fatty acid substrates. We previously identified Rv0098 as a long chain (C12-
C18) fatty acyl-CoA thioesterase. It, taken together with the structural analyses and 
enzymatic characterization of FadD10 (Rv0099), suggests that the lipopeptide produced 
by the M. tuberculosis Rv0096-Rv0101 operon incorporates a long chain fatty acid, 
particularly tetradecanoic acid that demonstrated the highest activity to acylate the ACP 
(Rv0100). 
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Figure 4-5. Biochemical and structural analyses suggest the biological substrate of FadD10. 
(A) Schematic representation of the hydrogen bonds (dotted lines) and hydrophobic interactions 
(bows) between dodecanoyl-AMP and FadD10.  
(B) The fatty acid binding tunnel of M. tuberculosis FadD10. The hydrophobic, positive, 
negative, and neutral surfaces of FadD10 are colored yellow, blue, red, and grey, respectively. 
Dodecanoyl-AMP is shown in stick and colored in pink. The arrows indicate the distance from 
the terminal carbon of dodecanyl chain to the molecular surface of the binding tunnel, taking into 
account of atomic van der Waals radii.  
(C) ESI-QTOF mass spectrometry of the holo-ACP (Rv0100) acylated by M. tuberculosis 
FadD10, in addition of fatty acids with varying chain length and degree of saturation. The ratio 
of abundance between the unreacted holo-ACP and the acylated ACP is approximately 1:5.5, 
1:6.9, 1:1.5, 1:0.6, and 1:0, respectively, for C12, C14, C16, 2-trans-C16, and C17 fatty acid. 
(D) FadD10 was incubated with dodecanoic acid, ATP, and cysteine, and then analyzed by LC-
MS. The result is simplified for clarity by only showing the elution of dodecanoic acid, 
dodecanoyl-AMP, and dodecanoyl-cysteine. 
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ATP-dependent amide bond synthesis activity has been previously reported for 
the short chain acyl-CoA synthetases as well as for firefly luciferase(Tomoko Abe et al., 
2008). Specifically, this was observed when cysteine analogues, including D-cysteine, 
homocysteine, and L-cysteine, were used as substrates to react with the preferred acid 
substrate of each enzyme. N-acylated cysteine derivatives were detected(Tomoko Abe et 
al., 2008). We have observed a similar activity in FadD10 using cysteine as a substrate 
(Figure 4-5 D). Unlike the side reactions observed in short chain acyl-CoA synthetases 
and firefly luciferase, whose amide forming activity is limited to cysteine 
analogues(Tomoko Abe et al., 2008), FadD10 is promiscuous with respect to other 
amino acids, specifically histidine, aspatate, glycine, and phenylalanine as we have 
tested (data not shown). Other amide synthetases belonging to the adenylate-forming 
superfamily have been reported. NovL, CloL, CouL, and SimL involved in novobiocin, 
clorobiocin, coumermycin A1, and simocyclinone D8 synthesis, respectively, can 
catalyze the formation of an amide bond between the amino group on the 
aminocoumarin ring and a carboxylate moiety through forming an adenylated 
intermediate(Elisabeth Schmutz et al., 2003; Florence Pojer et al., 2002; Marion 
Steffensky et al., 2000; Thomas Luft et al., 2005). Similar to fadD10, these four enzymes 
are in proximity to and cooperate with NRPS encoding genes. This suggests that amide 
formation, a side reaction to thioesterification of adenylate-forming enzymes, may 
evolve into a major biological function. 
Superposition of FadD10 with acyl-CoA synthetase complexed with Coenzyme 
A derivatives shows that the phosphopantetheine binding cavity is in the N-terminal 
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domain of FadD10. In our two structures, the continuity between the phosphopantetheine 
cavity and the fatty acyl binding tunnel is blocked by the side-chain of H225. A 
conserved aromatic residue (either histidine, phenylalanine, or tryptophan), equivalent to 
H225 in FadD10, is found in the sequences of all of the adenylate-forming enzymes. It is 
thought to function in the proper positioning of a fatty acid substrate into its cognate 
binding tunnel instead of extending into the phosphopantetheine binding site. More 
clearly described in the human medium chain fatty acyl CoA synthase(Grazyna Kochan 
et al., 2009), the indole ring of W265 (equivalent to H225 in FadD10) rotates about 180 
degrees relative to the main chain in the ATP or Coenzyme A binding state. This action 
switches off and on the connection between the fatty acid binding tunnel and the 
phosphopantetheine binding cavity. FadD10 should adopt a similar scheme to reorient 
H225 in the context of the overall reaction in order to allow for the extension of the 
phosphopantetheine terminus of the ACP (Rv0100) in to the fatty acid binding site. 
 
Conclusion 
We have determined the apo and dodecanoyl-AMP bound structures of M. 
tuberculosis FadD10, leading to the characterization of a new type of adenylate-forming 
enzyme. FadD10, independent of the presence of ligand, adopts and maintains an “open” 
conformation wherein the inter-domain orientation prevents the binding of Coenzyme A. 
Although M. tuberculosis FadD10 has a primary sequence similar to FACLs, we have 
clearly shown that it is indeed an FAAL that is only able to acylate an ACP (Rv0100) 
rather than Coenzyme A. This activity is consistent with the structural features of 
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FadD10; and is in agreement with the operon organization of M. tuberculosis Rv0099 
(FadD10) – Rv0101 (nrp), an assembly line for the production of lipopeptide(s). 
Because many similar gene clusters, involving an FAAL, an ACP, and an NRPS, have 
been observed in the synthetic pathways for bioactive lipopeptides(Darren Hansen et al., 
2007; Erwin Duitman et al., 1999; Eva Heinzelmann et al., 2005; Richard Baltz et al., 
2006), therefore it is very likely that enzymes with similar mechanisms and structures to 
M. tuberculosis FadD10 will be discovered in nature. 
 
Experimental Procedure 
Cloning, protein expression, and purification 
The M. tuberculosis fadD10 (Rv0099) gene was amplified by PCR, incorporated 
into the pDEST17 vector by gateway cloning (Invitrogen), and then transformed into 
either Novagen BL21(DE3)pLys E. coli cells for expression of native protein or 
Novagen B834(DE3)pLys cells for selenomethionine-incorporated protein expression. 
The cells were cultured at 37 °C until an OD600 of 0.8 was reached. For native 
protein expression, 1mM isopropyl-1-thio-β-D-galactopyranoside (IPTG) was added to 
induce expression and the cells were grown overnight at 20 °C. For selenomethionine-
incorporated protein expression, the cells were collected at an OD600 of 0.8, centrifuged, 
then resuspended and transferred into minimal media with selenomethionine. Induction 
of expression and growth were the same as for the native protein. 
After harvesting, the cells were resuspended in 25 mM Tris (pH 8.0), 500 mM 
NaCl and 2 mM β-mercaptoethanol, and lysed by French press. Recombinant FadD10 
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with an N-terminal poly-His tag was purified by nickel affinity chromatography 
followed by gel filtration. The His6 tag was then cleaved by TEV protease and the 
untagged protein was passed through another nickel column in 25 mM Tris (pH 8.0), 
100 mM NaCl and 2 mM β-mercaptoethanol. It was then concentrated to 15 mg mL-1, 
flash-frozen, and stored at -80 °C. 
The M. tuberculosis Rv0100 gene was amplified by PCR, ligated into the 
Novagen pET28b vector. The E. coli phosphopantetheine transferase Sfp was cloned into 
Novagen pETduet-1 vector. The plasmids containing Rv0100 and Sfp, respectively, were 
co-transformed into Novagen BL21(DE3) E. coli cells, and then expressed as described 
for the native FadD10. Recombinant holo-Rv0100 with a His6 tag was purified by nickel 
affinity chromatography in 25 mM Tris (pH 8.0), 100 mM NaCl and 2 mM β-
mercaptoethanol. 
 
Crystallization 
Crystals of Se-FadD10 (selenomethionine incorporated) were grown at 18 °C by 
hanging drop vapor diffusion. Each drop contained an equal volume of the protein 
solution and reservoir solution (0.32-0.36 mM LiSO4 and 15-30% polyethylene glycol 
6000). 
FadD10 in complex with dodecanoyl-AMP was obtained by incubating the 
protein solution for one hour with the reaction mixture in a 10:1 volume ratio. The 
reaction mixture was made by incubating 10 µM FadD10 with 2.5 mM ATP, 10 mM 
MgCl2, and 1 mM dodecanoic acid for one hour at 37 °C, then filtering out the protein 
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and concentrating the mixture ten-fold. Crystals formed in hanging drops after four days 
in 4 M potassium formate. 
 
Data collection and processing 
Diffraction data from a single apo Se-FadD10 crystal was collected at 120 K 
using a cryo-protection solution consisting of the crystallization condition with the 
addition of 30% glycerol. Crystals diffracted to 2.20 Å at beam line 5.0.2 at the 
Advanced Light Source (ALS). A total of 180° diffraction data were collected at the 
wavelength of 0.9795 Å, which is the absorption peak of Se-FadD10 crystals. 
Diffraction data of FadD10 in complex with dodecanoyl-AMP were collected to 2.44 Å 
at the wavelength of 1.542 Å using Rigaku R-AXIS IV++ at home source. All the data 
were processed and reduced using HKL2000(Zbyszek Otwinowski and Wladek Minor, 
1997). The crystals of apo Se-FadD10 are in the space group P21, with two molecules in 
each asymmetric unit. The crystals of FadD10 binding dodecanoyl-AMP are in the space 
group P3121, with one molecule in each asymmetric unit (Table 4-1). 
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Table 4-1. Data collection and refinement statistics for FadD10 structures. 
PDB ID 4ISB 4IR7 
Crystal Se-FadD10 C12-FadD10 
Ligands SO42- dodecanoyl-AMP 
  Mg2+ 
Data collection 
Space group P21 P3121 
Unit cell dimensions 
 
a=57.32Å, b=107.91Å, 
c=85.69Å 
a=90.0°, b=106.9°, g=90.0° 
a=b=138.16Å, c=82.47Å 
a=b=90.0°, g=120.0° 
 
Molecules/ASU 2 1 
Wavelength (Å) 0.9795 1.542 
Resolution (Å) 48.57-2.20 39.84-2.80 
Completeness (%)1 99.3 (98.9) 100.0 (99.7) 
No. of reflections 49204 24707 
I/σI* 9.50 (1.94) 14.01 (2.15) 
Rsym* 0.103 (0.703) 0.0567 (0.504) 
Refinement statistics 
Resolution (Å) 48.50-2.20 39.03-2.80 
No. of reflection work 49014 22632 
No. of protein atoms 7422 3734 
No. of water molecules 59 32 
No. of heteroatoms 20 36 
Rcryst (%) 22.69 22.61 
Rfree (%) 27.28 27.95 
RMSD bond length (Å) 0.01 0.002 
RMSD angle (°) 1.26 0.60 
Mean temperature factor (Å2) 25.5 62.0 
*. Numbers in parenthesis indicate data for highest-resolution shell. 
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Structure determination and model refinement 
The phase of Se-FadD10 was determine by single-wavelength anomalous 
dispersion using Autosol in PHENIX(Paul Adams et al., 2010). Twenty-two selenium 
atoms were located and refined per asymmetric unit till the overall figure of merit 
reaches 0.32. An initial model was built by Autobuild in PHENIX(Paul Adams et al., 
2010). Manual rebuilding was then performed to improve the model using Coot(Paul 
Emsleya and Kevin Cowtan, 2004). The final model was obtained after further cycles of 
model building and PHENIX refinement yielding Rcryst and Rfree of 22.69% and 27.28%, 
respectively. There are two subunits, designated as A and B, as well as 4 sulfate ions and 
59 water molecules per asymmetric unit in the refined model. A total of 508 and 502 out 
of 540 residues for chain A and B, respectively, were visible and built into the electron 
density. The missing residues are due to the absence of interpretable electron density. 
They include the N-terminal residues 1-8, the C-terminal residues 532-540, and the loop 
residues 145-154, 424, 477-480 of chain A; and the N-terminal residues 1-3, the C-
terminal residues 532-540, and the loop residues 125-131, 145-154, 161-164, 179-183 of 
chain B. Residues S178, T181, E183, and K185 of chain A and residues E426, R451, 
S474, E476, and L477 of chain B were built as alanine due to ambiguous side chain 
electron density. 
The structure of FadD10 in complex with dodecanoyl-AMP was solved by 
molecular replacement using MOLREP (Alexei Vagin and Alexei Teplyakov, 1997) in 
CCP4. A single solution for the molecular replacement was obtained using the chain A 
of apo FadD10 as the search model. Dodecanoyl-AMP was manually built in the model 
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by examining the Fo – Fc map in Coot(Paul Emsleya and Kevin Cowtan, 2004). The 
final model was obtained after further cycles of model building and PHENIX 
refinement, to 2.80 Å, yielding Rcryst and Rfree of 22.61% and 27.95%, respectively. 
There are one subunit of FadD10, one dodecanoyl-AMP, and 32 water molecules in each 
asymmetric unit. A total of 508 residues are built into the refined model. The N-terminal 
residues 1-10, the C-terminal residues 532-540, and the loop residues 124-128, 147-152, 
179-180 are missing from the model due to the absence of interpretable electron density. 
The complete refinement statistics are given in Table 1. 
 
Enzymatic assays to detect acylation of Rv0100 
FadD10 (1.5 µM) and Rv0100 (20 µM) were incubated with 2 mM ATP, 5 mM 
MgCl2, in presence of 200 µM different fatty acids, in 25 mM ammonium bicarbonate 
buffer at pH 7.8, for 1 hour. The salts were removed by diluting and concentrating the 
solutions by 10-fold in 25 mM ammonium bicarbonate buffer, for 3 cycles. The resulted 
samples were mixed with acetonitrile and formic acid in a ratio of 1:1:0.002, and then 
analyzed by Bruker microQTOF-QII. 
 
HPLC-MS analysis of dodecanoyl-amino acids 
FadD10 (10 µM) was incubated with 2 mM ATP, 8 mM MgCl2, 200 µM 
dodecanoic acid, in presence of 2 mM different amino acids, in 50 mM phosphate buffer 
at pH 6.5, for 1 hour. The macromolecues were removed by passing the solutions 
through 5 kDa cutoff filters. 100 µL of each reaction product were injected in to HPLC 
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coupled with ESI-MS analysis. The HPLC was performed with an Atlantis T3 5 µM 
column (4.6, 250 mm), using a 5% acetonitrile/0.1% TFA wash for 10 minutes followed 
by a 5%-80% acetonitrile/0.1% TFA gradient over 1 hour. 
 
Additional Unpublished Results 
Kinetics of the adenylation activity of FadD10 
The adenylation activity of M. tuberculosis FadD10 was monitored by a 
phosphate detecting enzymatic assay. The enzyme displayed Km values of 106 µM 
(Figure 4-6 A and B) and 46 µM (Figure 4-6 C) for ATP and dodecanoic acid, 
respectively. The Kcat was determined to be 0.005 s-1 (Figure 4-6 B). These kinetic 
parameters are comparable to those reported for the adenylation reaction catalyzed by 
FAAL enzymes. For example, Mycobacterium smegmatis FAAL32 showed Km of 20 
µM and 250 µM for dodecanoic acid and ATP, respectively(Ségolène Galandrin et al., 
2013); E. coli FAAL showed Kcat of 0.001 s-1 using octyldecanoic acid as 
substrate(Zhening Zhang et al., 2011). We have also examined the overall acyl transfer 
activity of FadD10 by incubating the enzyme, ATP, dodecanoic acid (C12 acid), in 
addition to both Coenzyme A and the holo-ACP (Rv0100). The resulted adducts were 
analyzed by ESI-QTOF mass spectrometry, where no dodecanoyl-CoA but only 
dodecanoyl-ACP was detected (data not shown). 
  116 
 
Figure 4-6. Kinetics of the adenylation activity of FadD10. (A) The absorbance spectrometry 
with 50 µM dodecanoic acid and varying concentration of ATP. (B) and (C) The Lineweaver-
Burk plots to determine the Km of ATP and dodecanoic acid, respectively. 
 
Gel filtration analysis of the interaction between FadD10 and Rv0100 
 The interaction between M. tuberculosis FadD10 and the ACP (Rv0100) in 
solution has been examined by gel filtration chromatography using Sephacryl S-200 HR 
from GE Healthcare. When equimolar mixture of FadD10 (~5 mg/mL) and holo-Rv0100 
(~1 mg/mL) was passed through the column, part of Rv0100 was associated to FadD10 
(Figure 4-7); but pure holo-ACP only eluted at the volume as observed for the free 
Rv0100 in Figure 4-7. This confirms our modeling studies of the interaction between the 
two proteins. The same was observed for apo-Rv0100 (the wide-type Rv0100 without 
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phosphopantetheination) as well (data no shown), which suggests that the interaction 
between FadD10 and Rv0100 is likely driven by interactions at the inter-molecular 
interface or a desolvation process, rather than being determined by phosphopantetheine 
binding. 
 
 
Figure 4-7. Gel filtration analysis of the interaction between FadD10 and Rv0100. The first peak 
corresponds to FadD10 associated with Rv0100, and the second peak corresponds to free 
Rv0100. 
 
Additional Unpublished Experimental Procedures 
Enzymatic assays for adenylation activity 
The adenylation reaction catalyzed by FadD10 is monitored by measuring the 
released pyrophosphate(Martin Webb, 1992). Each reaction (180 µL) contained FadD10, 
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dodecanoic acid, ATP, and 50mM Tris-HCl (pH 7.5), 10 mM MgCl2, 550 mM 2-amino-
6-mercapto-7-methylpurine riboside, which was coupled to 0.1 unit pyrophosphatase 
(Sigma-Aldrich) and 0.2 unit purine nucleoside phosphorylase (Sigma-Aldrich). The Km 
of dodecanoic acid was determined with 7 µM FadD10, 1mM ATP, and dodecanoic acid 
varying from 0 to 100 µM; and the Km of ATP was determined with 3.3 µM FadD10, 50 
µM dodecanoic acid, and ATP varying from 100 µM to 3 mM. All the reactions were 
read at 360 nM by Thermo Scientific Multiskan GO microplate spectrophotometer. 
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CHAPTER V 
CONCLUSION 
 
 In this thesis, I highlighted my work with peers on the proteins involved in the 
lipid metabolism of M. tuberculosis. In CHAPTER I, I presented the literature review on 
the physiological significance of lipid metabolism in M. tuberculosis, and the prospects 
of lipid metabolic pathways as targets for anti-tubercular drug design. In CHAPTER II, I 
characterized the binding of dioctylamine with the methyltransferase CmaA2, designed 
an enzymatic assay, and demonstrated the inhibition action of dioctylamine on CmaA2 
in vitro. This work, coupled with my collaborators’ in vivo examination, showed that 
dioctylamine had tentative antimicrobial activity and could serve as a framework to 
design more potent inhibitors. This research also validated the mycobacterial 
methyltransferases (CmaA2 and homologues) as promising drug targets. In CHAPTER 
III, I presented my work with peers on the understanding of the action of INH and ETH. 
They are pro-drugs that are metabolized intracellular and thus the action is largely 
complicated. Using technologies covering microbiology, structural biology, 
enzymology, and computation, we confirmed the target of INH and found out a new 
cellular component to affect ETH susceptibility. In CHAPTER IV, I showed the 
characterization of the enzyme FadD10. It is virulence associated yet its function was 
previously mysterious. Through delicate analyses of its sequence, activity, and structure, 
I identified the enzyme as a fatty acyl-ACP synthetase and elucidated the molecular 
basis of its action. 
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Since the bacterium of M. tuberculosis was discovered more than a century ago, 
TB continues to reign as the single leading cause of death by an infectious disease. 
Instead of being eliminated from the human society, the bacterium has developed into 
more fatal formats, i. e. MDR- and XDR-TB strains. This is largely due to a chronicle 
use of a small category of anti-tubercular drugs. Therefore scientists from different 
fields, such as microbiology, enzymology, biophysics, and informatics, have been 
thriving to come up with new strategies to fight against this persistent bug. I hope our 
efforts to try to understand and target the lipid metabolism of M. tuberculosis will 
provide a new perspective in the understanding of infection mechanism, the validation of 
new drug targets, and the design of new drugs. 
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APPENDIX 
AUTHOR CONTRIBUTIONS FOR THE REPRINTED ARTICLES 
 
CHAPTER II: 
Daniel Barkan analysed the whole cell response (including M. tuberculosis, M. 
smegmatis, and BCG strains) to dioctylamine, in terms of the mycolic acid profiles and 
susceptibility to antibiotics. 
Zhen Liu carried out in vitro characterizations including fluorescence titration, 
enzymatic assays, and crystallography; performed the fragment-based screening for 
CmaA2. 
CHAPTER III: 
Feng Wang carried out the biochemical and structural characterization for DhfR. 
Catherine Vilchèze isolated the spontaneous mutants of M. tuberculosis, co-resistant to 
INH and ETH, and located the mutations to mshA. 
Zhen Liu carried out the biochemical and structural characterization for InhA co-
expressed with KatG; analyzed the model of M. tuberculosis MshA; and performed the 
enzymatic assays for EthA. 
 
